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Abstract 
To ensure the effective and safe use of nanomaterials for medical applications, the biocompatibility of the 
materials must be tested with particular relevance to the environment in which the material is placed. In 
nanoparticle-based drug delivery, it is crucial to evaluate a nanoparticle’s biocompatibility to ensure 
minimal cytotoxicity. Of several types of nanoparticles, peptide-based nanoparticles have emerged as 
promising systems for targeted cancer therapy. Yet, the biocompatibility of many of these peptides and 
their assembled particles has not been studied. This thesis, summarizes the original contribution on the 
effective and safe use of the particular self/co-assembling, amino acid pairing peptides and some of their 
DEGylated forms (modified versions) as carriers for anticancer drug delivery application. 
Therefore, the biocompatibility of the self-assembling, amino acid pairing (AAP) peptides AC8, its two 
DEGylated forms, as well as two related peptides, EAK16-II and EK8, is systematically investigated. The 
toxicity of these peptides and their complexes with pirarubicin was tested against the human 
adenocarcinoma lung cancer cell line, A549.The biocompatibility of the peptide-drug co-assembling 
complexes is assessed and the potential of these five peptides as carriers for the hydrophobic anticancer 
drug pirarubicin is demonstrated. For the first time experimental results on cytotoxicity, haemolytic 
activity, red blood cell (RBC) aggregation, complement activation and anaphylotoxin activation as an end 
result of complement activity for these five AAP peptides is reported. AC8, the amino end DEGylated 
AC8 (NP-I) and EK might be strong candidates for hydrophobic drug delivery considering their lack of 
toxicity and the fact that they are not recognized as a foreign molecule, inducing no considerable immune 
reactions. These results provide a basis for in vivo experiments and predict minimal in vitro toxicity of 
these peptides based delivery systems.  
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Chapter 1 
Introduction 
1.1 Overview 
The rapid advancement of nanotechnology has allowed the possibility of using engineered 
nanoparticles that interact within biological environments for treatment of diseases. As a 
result, nanoparticles have the potential to revolutionize a wide range of medical diagnostic 
and therapeutic interventions such as diagnostic aging (1-3), photothermal therapy (4), nucleic 
acid delivery (5-7), plantable devices, and of particular interest in this thesis, drug delivery 
(8). The interaction of nanoparticles interacting with cells and the extracellular environment 
can trigger a sequence of biological effects. These effects largely depend on the dynamic 
physicochemical characteristics of nanoparticles, which determine the biocompatibility and 
efficacy of the intended outcomes.  
To ensure an effective and safe use of nanomaterials for medical applications such as drug 
delivery, the interaction between a material and the biological system of interest must be 
studied and characterized. Therefore, studies of a material's biocompatibility must be 
conducted with particular focus on the environment in which the biomaterial will be placed 
(9).  
As a result, in drug delivery, it is crucial to evaluate a nanoparticle's biocompatibility to 
ensure safe drug release and minimize cytotoxicity. Indeed, a thorough evaluation of the 
factors that affect the biocompatibility of nanoparticles is central and possibly a ﬁrst key step 
for the development of a safe delivery system for drugs. It is not surprising then that 
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biocompatibility evaluation of engineered nanoparticles for drug delivery applications has 
been expanded from being primarily investigated in a laboratory setting to being applied in 
the multi-billion dollar pharmaceutical industry (10). It is now well known that the inherent 
physical and chemical properties of nanoparticles (size, shape, surface characteristics) as well 
as the environment it comes into contact with, can dictate a nanoparticle's degree of 
biocompatibility (11-13). For instance, the route of a material's delivery into the body such as 
intravenous or oral intake will induce differential immune reactions (11). The immune 
reaction cascade can be initiated with the adsorption of opsonins to the surface of 
nanoparticles. Opsonins are proteins – such as immunoglobulins or complement proteins – 
that bind to microbes and foreign substances and in doing so, aid their clearance via 
phagocytosis. Opsonin adsorption, enhanced by the hydrophobicity of a particle's surface, can 
mark nanoparticles as foreign substances and increase their uptake by the phagocytic cells 
(14, 15) This uptake in turn determines the route of particle internalization (16-18) and 
consequently dictates the fate of nanoparticles in the body (19). This process is one of the 
biological barriers to nanoparticle-based controlled drug delivery (20). All of these together, 
highlight the importance of surface effects for nanoparticles to be used as a carrier for drug 
delivery. A number of studies have reported that the response of biological systems to 
nanoparticles is related more to its surface properties rather than its mass (21-25). For 
example, Nel et al. provided the theoretical and methodological framework that describes the 
biophysico-chemical interactions at the interface of nanoparticle surface and the biological 
environment, including contact with cells (26). As reported in most studies, nanoparticles with 
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no surface modiﬁcation are mostly taken up by phagocytic cells, which may cause undesirable 
interaction between nanoparticles and the immune system, and lead to a decrease in the drug's 
bioavailability as well as an increase in toxicity for the host. Consequently, the question of 
whether nanomedicine tools could mark an end to the necessity for “smart” drug delivery 
systems remains until a better understanding of the concept of biocompatibility is achieved 
and represents a major area of interest in the ﬁeld of drug delivery.  
Here,  some data regarding the biocompatibility and peptide- based nanoparticles in the 
context of drug delivery is presented. More specifically, in this research , the biocompatibility 
of a new class of self-assembling peptides which contains all complementary amino acid pairs 
in its sequence and thus the name, amino acid pairing (AAP) peptides was investigated to 
show their potential to be used as carriers.  The selected peptides are AC8 plus its modified 
versions (DEGylated forms) as well as EAK16-II and EK8 per se and with the hydrophobic 
anticancer drug pirarubicin. This further allows for the testing of peptide-based nanoparticles 
for targeted drug delivery as well as prediction of the possible toxicological reactions to such 
nanomaterials (biocompatibility). 
1.2 General Goal and Research Objectives 
The goal of this research was to evaluate biocompatibility of amino acid pairing (AAP) peptides  when 
they are used as a carrier for anticancer drug delivery. The hydrophobic anticancer drug Pirarubicin 
is the candidate to examine this purpose. The AAP peptides which will be assessed are: AC8, AC8-
DEG, and DEG-AC8-DEG, EAK16-II and EK8.  
The specific objectives of this thesis were to: 
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1- Investigate haemolytic activities of the above mentioned AAP peptides and peptide-
Pirarubicin-co assemblies (complexes). 
2- Study complement activation caused by AAP peptides and complexes. 
3- Examine anaphylotoxin activation by these peptides. 
4- Understand the toxic effects of AAP peptides and evaluate the therapeutic effect of the 
peptide-drug complexes in vitro with cancer cell line A-549, a human lung cancer cell. 
5- Elucidate the potential ability of these peptides to be utilized as carriers for the delivery of the 
hydrophobic anticancer drug pirarubicin. 
1.3  Outline of the Thesis 
This thesis consists of six chapters. The scope of each chapter is listed as follows: 
Chapter 1 gives an introduction to the thesis, including an overview of biocompatibility and 
the immune reaction cascade which can dictate the fate of nanoparticles. The significance of 
the study and its application in drug delivery are also addressed. The goal, objectives and the 
outlines of the thesis are given in this chapter. 
Chapter 2 reviews the background on understanding biocompatibility of nanoparticles and 
relevant factors that should be considered for biocompatibility evaluation of nanoparticles. In 
addition, immunocompatibility- as a subcategory of biocompatibility- as well as the roles that 
physicochemical properties of nanoparticles in biological systems play  are also reviewed. 
Additionally, the major obstacle to drug delivery addressed and the concept of self-
assembling, ionic-complementary self-assembling and amino acid pairing (AAP) peptides is 
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briefly  reviewed. Finally, the importance of regulatory agencies highlighted and chapter 
concluded. 
Chapter 3 describes the in vitro biocompatibility and toxicity of amino acid pairing peptide 
AC8 and its potential application for use as a carrier for drug delivery 
Chapter 4 examines how functionalization by conjugating amino acid pairing peptide AC8 
(AAP8) to diethylyne glycol (DEG) in two different fashions can affect biocompatibility.  
Chapter 5 investigates the nanotoxicity of self/co-assembling peptide EAK16-II and EK8 to 
be used as carrier for anticancer drug, Pirarubicin 
Chapter 6 presents the summary of outcomes of this study, original contributions of this 
research and recommendations for future work. 
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Chapter 2* 
Literature Review  
2.1 What is biocompatibility? 
Biocompatibility ﬁrst drew the attention of researchers between 1940 and 1980 in the context 
of medical implants and their interaction, both harmful and beneﬁcial, with the body. Only  
within the past two decades, has this term been formally deﬁned under its conceptual 
denotation rather than practical description (9): “The ability of a material to perform with an 
appropriate host response in a speciﬁc situation” (27). The three dogmas which play important 
roles in this deﬁnition are that a material has to perform its intended functions and not merely 
be present in the tissue, that the induced reaction has to be proper for the intended application, 
and that the nature of the reaction to a particular material and its suitability may be different 
from one context to another (28).  
   In 2010, Kohane and Langer explained biocompatibility in the context of drug delivery and 
deﬁned biocompatibility as “an expression of the benignity of the relation between a material 
and its biological environment” (10). However, some researchers have expanded that 
deﬁnition by denoting acceptable functionality of a biomaterial in a given biological context 
as important (10). As such, Williams has reviewed the biocompatibility concept for long-term 
implantable medical devices and tissue engineering products in detail (9). In general, a high 
degree of biocompatibility is achieved when a material interacts with the body without 
                                                     
* Most parts of this chapter were published as Sheva Naahidi, Mousa Jafari, Faramarz Edalat, Kevin Raymond, 
Ali Khademhosseini, P. Chen, Biocompatibility of engineered nanoparticle for drug delivery, Journal of Controlled Release 
166 (2013) 182–194 
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inducing unacceptable toxic, immunogenic, thrombogenic, and carcinogenic responses 
(Figure 2-1).  
There are a number of relevant factors that should be considered for the evaluation of 
biocompatibility. First, biocompatibility is highly anatomically reliant which leads to the fact 
that the reactions to particular materials are different from one location to another. For 
instance, biodegradable polymeric-based nano- and microspheres – such as those based on 
poly(lactic-co-glycolic acid) (PLGA) – in general make a well characterized, subjectively 
mild tissue reaction, whereas the same particles introduced in the loose connective tissue 
surrounding nerves cause fairly strong acute inﬂammations (10, 29-31). Therefore, another 
fact that one must be cognizant of is that, if a biomaterial for a particular application can 
cause an adverse effect in a speciﬁc tissue type, it will not necessarily provoke the same 
response if used for a different application or in a different tissue type.  
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Figure 2-1 When nanoparticles interact with the body, a variety of responses may occur. These include 
alterations to the immune system or interaction with blood, among others. These reactions vary 
significantly with nanoparticle composition. For example, gold nanostructures may interact differently 
with the body when compared to polymeric particles. For this reason, nanoparticles have to be evaluated 
individually or “on a case-by-case basis” to better understand their effect on the body (32).   
Second, and in an interrelated perspective, the biomaterials’ intrinsic characteristics 
exclusively will not determine whether that particular material is biocompatible or not. For 
instance, PLGA nanoparticles those have a rapid clearance from the body do not usually cause 
peritoneal adhesion, whereas PLGA microparticles which stay longer in peritoneal cavity, do 
cause peritoneal adhesions (10, 33). Therefore, the exposure half-life is another important 
factor that deserves consideration. Third, biocompatibility is a relative matter that depends on 
the risk-beneﬁt ratio, and relies on a subjective declaration since, in general, inﬂammation 
would totally vanish over time, and the neighboring tissues do not exemplify a good proof of 
damage. Last, but perhaps most important, the lack of adequate data regarding biological 
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processes in response to foreign materials, as well as the insensitive nature of the methods 
available for biocompatibility has limited the understanding of the biocompatibility of 
materials. All this together highlights the necessity of biocompatibility evaluation of 
biomaterials in a case-by case and tissue- and application-speciﬁc manner. Bringing all these 
together, I can conclude that biocompatibility of materials depends on their structure, 
formulation and many other factors as described above and can refer to a local or total effect 
on the organism. Accordingly, using biocompatible materials in an absolute sense, would be 
misleading (30, 31, 34-44).  
2.2  Immunocompatibility 
Immunocompatibility or the study of the immune response to a biomaterial, prosthesis, or 
medical device, as a subcategory of biocompatibility, represents a major area of interest. 
While factors such as the interaction with blood components, particle accumulation, and 
clearance in organs are indeed important, alterations to the immune system cannot be ignored. 
Nanoparticles have the potential to either stimulate or suppress the immune system, a property 
that may positively or adversely affect the function of a particle for particular applications. 
2.2.1 Immunostimulation 
As various compounds or materials are introduced into the body, the immune system 
recognizes them as foreign and elicits a multi-level immune response. When this occurs, the 
activity of one or more components of the immunoregulatory complexes is directly enhanced, 
and immunostimulatory effects such as ﬂu-like symptoms and hypersensitivity to unrelated 
allergens are observed (45). Chamberlain and Mire-Sluis have described the molecular 
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structure, architecture of folding motifs, degradation products, formulation, package purity, 
and stability of pharmaceuticals as factors responsible for immunostimulation (46). 
Furthermore, Rihova and Kovar report that factors such as dose, route and time of 
administration, mechanism of action, and site of activity – all of which are extrinsic to the 
material – are also critical in immunostimulation (47). As part of immunostimulation, 
nanoparticles have displayed adjuvant properties. Adjuvants are substances that enhance the 
body's immune response to an antigen. In the context of cancer, pharmaceuticals are 
considered adjuvants when they, by stimulation of the immune system, suppress secondary 
tumor formation following treatment. Stieneker et al. showed that poly(methylmethacrylate) 
(PMMA) nanoparticles, when used as an adjuvant in human immunodeﬁciency virus (HIV) 2 
whole-virus vaccine, were able to produce an antibody response in mice that was 100 times 
stronger than the traditional aluminum hydroxide or aqueous control vaccine (48). Caputo et 
al. showed that novel biocompatible anionic microspheres are suitable and efficient storage 
and delivery systems for HIV-1 Tat protein for vaccine applications that preserve protein 
conformation and activity (49). In particular, they have shown in vitro that anionic nano- and 
microspheres attach the HIV-1 Tat protein and guard it from oxidation; therefore, rising the 
“shelf-life” of the Tat protein vaccine (49, 50). In addition, in this group, in vivo 
biocompatible and novel surfactant-free polymeric core–shell nanoparticles and 
microparticles were developed (49-51). These particles reported to be able “to accommodate 
in their shell high amounts (antigen loading ability of up to 20%, w/w) of native proteins, 
mainly by ionic interactions, while preserving their activity” (52). However, recent progress 
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in the development of HIV-1 Tat-based vaccines (53) from basic science to clinical trial (54) 
has been reviewed elsewhere. In a similar study by Castignolles et al. using rabies vaccine 
showed that lipid-coated polysaccharide nanoparticles increased antibody response, and hence 
vaccine efﬁcacy, fourfold (55). Works by Diwan et al. and Cui et al. suggest that 
nanoparticles exhibit adjuvant properties by enhancing antigen uptake and stimulating 
antigen-presenting cells (56, 57). While the mechanisms of nanoparticle-induced adjuvant 
properties are not fully understood, its proven effectiveness for use in vaccines has generated 
a great deal of interest. One of the critical components of immunostimulation is inﬂammation, 
a non-speciﬁc immune reaction whereby signaling molecules called cytokines are secreted to 
recruit immune cells to the location where foreign material exists. This recognition is 
triggered by the core composition and surface properties of the particle. Of these properties, 
surface charge plays a particularly important role; generally, a positively charged particle is 
more apt to cause inﬂammation than a neutral or negatively charged particle. This fact was 
corroborated by Tan et al., who showed that an anionic particle did not cause the secretion of 
cytokines while a cationic particle did (58). Diwan et al. provided further evidence of 
nanoparticle-induced inﬂammation. They showed that oligonucleotides bound to PLGA-based 
nanoparticles caused a larger amount of cytokine production and induced more T-cell 
proliferation than the naked oligonucleotide (59). Foreign material is dealt with and cleared 
from the body in a variety of ways. Nanoparticles can be engineered to resemble pathogens so 
they are dealt with in an equivalent fashion. One method of doing this is by modifying 
nanoparticles with Toll-like receptor (TLR) ligands, which are recognized by the immunity 
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system's dendritic cells. In one study, mannose was applied to modify the surface of particles, 
stimulating the particle's uptake by mannose receptors, a common mechanism for pathogen 
neutralization (60). However, there is a tremendous amount of work involved in focusing 
micro particle based immunostimulation against cancer cells. 
2.2.2  Immunosuppression 
Immunosuppression is described as the down-regulation or prevention of the activation of the 
immune system. Since the early 1960s, immunotoxicologists have continued to catalogue the 
immunosuppressive ability of drugs as well as chemicals. Immunosuppression has its 
drawbacks such as increasing susceptibility to infections caused by bacteria, viruses, fungi, 
and yeast (61), as well as the development of neoplasms (most commonly skin cancers and 
lymphomas) (62). While immunosuppression is undesirable in some instances, it has proven 
useful in the treatment of autoimmune diseases and has facilitated the acceptance of foreign 
tissues in organ transplant patients. As with immunostimulation, factors such as drug dose, 
pathway into the body, time of administration, the mechanism of action, and site of activity 
will affect the body's response to an immunosuppressant (47). Nanoparticles have been shown 
to produce immunosuppressant properties. For instance, Shaunak et al. (63) reported that 
when human macrophages and dendritic cells were exposed to the bacterial endotoxin, 
Generation-3.5 polyamidoamine (PAMAM) dendrimer-glucosamine conjugates – which are 
produced from partial modiﬁcation of carboxylic acid terminated PAMAM dendrimers with 
glycosamine – were able to significantly inhibit cytokine- and chemokine-induced 
inﬂammation with a novel immunomodulatory and antiangiogenic properties. Interestingly, 
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no hematological toxicity was apparent, suggesting that the dendrimer conjugates may be able 
to treat and prevent the formation of scar tissue (63). In another work, PLGA nanoparticles 
containing collagen type II suppressed arthritis-induced inﬂammation in a mouse model (64). 
A comparable study observed similar results using PLGA nanoparticles functionalized with 
betamethasone in rats (65). In a similar mouse model, autoimmune diabetes was inhibited 
(66). Cromer et al. reported that amino terminated generation-5 PAMAM dendrimers 
modiﬁed with 2-hydrohyhexyl groups protected against fatal sepsis and in vivo and in vitro 
cytokine secretion caused by bacterial lipopolysaccharide (67). 
In the case of allergies, the induction of immune tolerance is considered desirable. For 
instance, Ryan et al. showed that polyhydroxy C60, a type of water-soluble fullerene, was 
able to inhibit hypersensitivity reactions both in vitro and in vivo (68). In similar cases, it was 
reported that nanoparticles suppressed type I and type II allergies to common environmental 
and food allergens (69-73). In this scenario, however, data conﬂicting with the concept of 
desirable effects of nanomaterials have been also presented. For instance, Zogovic et al. 
investigated the inﬂuence of nanocrystalline fullerene C60 on tumor progression and reported 
that nanoC60, “in contrast to its potent anticancer activity in vitro, can potentiate tumor 
growth in vivo, possibly by causing NO-dependent suppression of anticancer immune 
response” (74). 
2.3  PEGylation 
The characteristics of a material's surface are a primary factor in the determination of the 
biocompatibility of that material within the body (11). This fact was recognized by 
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Abuchowski et al., who in the 1970s, were the ﬁrst to introduce the covalent bonding of poly 
(ethylene glycol) (PEG) to a drug or therapeutic protein in a process known today as 
PEGylation (75). Later on, in 1984, de Gennes described two main regimes or conformations 
that PEG chains can obtain which are called mushroom and brush conformation — depending 
on grafting density (76). If the grafting density is low, the PEG polymer is assumed to be in 
the mushroom regime. If the density is high the PEG polymers are assumed to be in the brush 
regime (77). The degree of surface coverage and distance between graft sites will depend on 
the molecular weight and the graft density of the PEG polymer (78); thus, requiring careful 
attention. Early work with PEG grafted nanoparticles pursued primarily from drug delivery 
(79-82). Davis and Abuchowski, as one of the ﬁrst reporters on PEGylation, described 
covalent attachment of methoxyPEGs (mPEGs) of 1900 and 5000 Da to bovine serum 
albumin and to liver catalase (75, 83). It is now well known that PEGylation holds many 
attractive properties; for instance, it has been shown to increase a drug's half-life within the 
body, prolonging the activity of the drug, and thus reducing the dosing frequency (84). In 
addition, in drug-delivery applications, PEG grafted nanocarriers decrease MPS uptake and 
augments circulation time versus uncoated counterparts (11). PEG's ability to prolong the 
circulation lifetime of the carrier (10) has been credited principally due to its physical 
properties (7, 75, 84, 85) which in turn can cause the reduction or prevention of protein 
adsorption. To this point, Allen et al. addressed the question of how surface of a liposome 
protected with PEG molecules of different molecular weights would differ from a PEG-free 
liposome (78). Their work was based on a previous approach established by Torchilin and 
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Papisov in 1994 (86). Needham and Kim reported that PEG of a selected molecular weight 
and graft thickness prevents the adsorption of certain proteins to a surface (84, 85, 87, 88); 
yet, there is not much evidence that exist for reduction of total serum protein binding due to 
surface PEGylation of carrier. Ahl et al. has shown that PEGylation increases a colloidal 
carrier's stability in vivo by its steric effect which acts as a barrier for aggregation (89). Other 
studies have suggested that PEG endorse binding of speciﬁc proteins that mask the carrier and 
cause “dysopsonization” (90, 91) as well as existence of attractive interactions between 
poly(ethylene glycol) and proteins (87, 91, 92). Not surprisingly, PEGylation can have ability 
to control the physical behavior and biological performance of nanocarriers formulations and 
as a result substantially change their biocompatibility. Consequently, PEGylation dramatically 
reduces the immunogenic response to a substance's surface, including a reduction in protein 
adsorption, as shown in Figure 2-2 (93), as well as a reduction in platelet aggregation, 
neutrophil activation, hemolytic activity, and coagulation (11).  
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Figure 2-2 PEGylated nanoparticles are able to avoid clearance from the blood stream by repelling 
protein adsorption, thus prolonging nanoparticle circulation time within the body (32).  
However, PEGylation also carries several disadvantages that must be considered. Recent 
works indicate the formation of PEG-speciﬁc antibodies, which clear the particle (along with 
the drug) from the body, thus reducing its effectiveness (47). In addition to this, obstacles 
include possible side reactions, incomplete PEGylation and the need for drug-speciﬁc 
tailoring (94).  
2.4  Nanoparticle Interaction with Blood 
The surface properties of nanoparticles can greatly affect their compatibility while in the 
blood stream. Interestingly, blood constituents can react immunologically to render 
nanoparticles and their drug complexes inactive. For instance, Gref et al. (79) reported that in 
the blood stream, macrophages rapidly clear nanoparticles that lacked surface modification to 
prevent the adsorption of opsonins. For this reason, preclinical examination of nanoparticle 
biocompatibility must include studies of hemolysis, platelet aggregation, coagulation time, 
complement activation, leukocyte proliferation, and uptake by macrophages (11). Therefore, 
 17 
 
evaluation of possible toxic effects of immediate exposure of nanoparticles would be the first 
critical step that one would be considered. It is known that erythrocytes exist in a larger 
volume portion of the blood than mononuclear phagocytic (MNP) cells. Thus, nanoparticles 
that were injected intravenously would encounter red blood cells (RBC) before MNP cells; 
consequently, examination of haemolysis is an instrumental part of preclinical studies of 
nanoparticles (12). Many authors reported hemolytic effects of different nanoparticles in the 
literature — as many of the studies have been conducted with blood to see the early toxic 
effects of nanoparticles. As a result, a number of mechanisms for drug mediated haemolysis 
have been recommended, yet the true mechanism has not been clearly identified. It is now 
well known that surface properties (especially surface charge) play an important role for 
nanoparticles and can directly damage erythrocyte membranes. For instance, in the presence 
of certain concentrations of unprotected primary amines (positive charge), red blood cell 
damage was observed on the surface of poly-amidoamine, carbosilane, polypropylene imine, 
and poly-lysine (95-100). However, a deeper understanding and knowledge on how the 
particulate nature of blood would affect a nanoparticle will help for improved design of 
nanoparticle-based drug delivery systems. In this regard, Tan et al. provided the theoretical 
and methodological framework that help to understand how interactions between blood cells – 
with and without red blood cell – and NPs influence the particle motion and binding (101). 
They reported enhance nanoparticle dispersion as well as 50% increased nanoparticle binding 
upon exposure to RBC. Another study also presented erythrocyte as a vital contributor to the 
process of transport and primary meeting of lymphocytes to the vascular wall (102). However, 
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there are other studies in the literature which reported mathematical or theoretical modeling of 
RBC on blood flow (103, 104) which indirectly would influence nanoparticles efficacy in 
drug delivery system. The complement system and its activation are major characteristics of 
the general host response to biomaterials, including nanoparticles. Complement activation is 
described as the recognition, opsonization, and clearing of pathogens and foreign material by 
approximately 35 typically dormant proteins present within blood (either solubilized in blood 
or located on the surface of blood cells) (94). The complement system can be triggered by any 
of three different pathways: the classical pathway, alternate pathway, and lectin pathway. 
These pathways are activated by different criteria: the classical pathway by specific antibodies 
found on the surface of the intruding material, the alternate pathway by the identification of 
certain microbial surface structures, and the lectin pathway by mannose residues found on 
microbial glycoproteins and glycolipids which are identified by mannose-binding lectin 
(MBL), a protein found in blood plasma (105). Understanding a material's effect on the 
complement system is crucial to understanding the immunological response it may trigger. 
For this reason, reducing a surface's tendency for complement activation has been the subject 
of widespread interest (106). 
2.5 Nanoparticles As Drug Carriers 
Nanoparticles used as drug carriers are submicron-sized particles ranging 100–1000 nm.  
Buzea et al. defined nanoparticles as “particles with at least one dimension smaller than 1 
micron and potentially as small as atomic and molecular length scales (~0.2 nm)” (107). 
Many organizations have now defined nanoparticles as the particles which should have a size 
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below 100 nm in at least one orthogonal direction. In fact, it is not easy to track expansions in 
the field of nanotechnology since the multidisciplinary nature of this field request a similar 
diversity of definitions in respect to each specialty or scientific discipline. In this regard,  
Klaessig et al. reported the dispute facing terminology and nomenclature efforts and listed the 
suggested upper boundary for the term nanoscale along with the organization, references and 
qualifications (108). Another example of such is the publication by the U.K. House of Lords 
Science and Technology Committee titled, “Nanotechnologies and Food” (109) and 
recommended: 
…We recommend…that any regulatory definition of nanomaterials 
… not include a size limit of 100 nm but instead refer to ‘the nanoscale’ to ensure that all 
materials with a dimension under 1000 nm are considered (108, 109). “The recommendation 
is that the term nanoscale have an upper boundary of 1,000 nm for the purpose of food 
regulations, rather than the ISO and ASTM International determinations that scientific usage 
is 100 nm.” (108).  
However, nanosized particles or nanoparticles used for drug delivery hold great promise for 
their feasibility as pharmaceutical carriers and can be prepared using a wide range of 
materials such as polymers, lipids, viruses, and organometalic compounds; therefore, their use 
in medicine is predicted to spread rapidly in the coming years (110). Studies indicate that 
nanoparticle-drug complexes have the ability to mitigate toxicity and side effects associated 
with raw pharmaceuticals such as chemotherapy drugs (11, 110), by allowing for targeted 
drug release and improved solubility through various methods such as encapsulation, 
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micellization, and protein cage architecture (111). Indeed, the potential for more precise 
localization and reduced toxicity of therapeutic drugs is encouraging. However, evidence 
suggests that nanocarriers themselves may pose a toxicological risk to patients beyond that of 
the taxied chemicals (110). De Jong and Bormhave summarized some of the adverse 
toxicological responses observed over the past decade, which include lung inflammation, 
platelet aggregation in blood, and impaired mitochondrial function in cells (110). As can be 
imagined, the toxicological effects vary with nanoparticle composition. The material 
composition may include metals and inorganic particles such as gold, silver, and metal oxides 
(112), polymer-based materials such as PLGA, and lipid-based particles such as 
nanoliposomes, solid lipid nanoparticles, and nanoemulsions. Each substance exhibits its own 
inherent physicochemical properties such as surface charge, hydrophobicity, solubility, size, 
shape, and aggregation tendencies which can be engineered to trigger different biological 
responses (8, 11). While the influence of such parameters on biocompatibility is well known 
in some instances, as schematically depicted in Figure 2-3 (11), investigations involving 
newer nanoparticle designs are still underway. As expected, the manipulation of these 
properties for the purpose of function and biocompatibility represents a prominent area of 
study in nanomedicine (8). 
 
 
 21 
 
 
Figure 2-3 The properties of nanoparticles such as size and charge determine their effect on the body (32). 
2.6 Types of Nanoparticles 
Nanoparticles exist in a wide variety of sizes, shapes, and compositions (113). Nanoparticle-
bound pharmaceuticals in their many forms can be found at various stages of the 
pharmaceutical pipeline; some have been approved for clinical use, while others are being 
tested and progressed through the approval process (11). In the following section, the focus 
will be on  nanoparticles that have been widely investigated for drug delivery applications. 
This section also outlines a variety of approaches to nanoparticle structure and composure. 
2.6.1  Carbon-based polymers  
Carbon-based polymers such as fullerenes, carbon dots, nanodiamonds, and nanofoams also 
represent a prominent area of nanoparticle research. Of these, fullerenes are well established 
and consist of C60, single-walled nanotubes, and multi-walled nanotubes. Carbon nanotubes 
 22 
 
have been proposed for use in a variety of contexts ranging from structural reinforcement of 
existing materials (114) to drug carriers (115). Carbon nanotubes are simple layers of graphite 
rolled in a tubular shape capable of exhibiting a single- or multi-walled morphology (116, 
117). Their cell-penetrating and conjugative properties make them a contender for in vivo 
drug delivery applications (115). In addition, surface functionalization can render typically 
heterogeneous nanotubes water-soluble (116). With regard to biocompatibility, carbon 
nanotubes have been shown to activate the complement system through the classical and 
alternate pathways (115). Furthermore, it was found that carbon nanotubes might, in some 
cases, over-stimulate the complement system, resulting in inflammation and granuloma 
formation (11, 115, 117). Additional factors that may inhibit carbon nanotube use in humans 
include evidence of oxidative stress (112, 116, 117), apoptosis (116), toxicity due to metal 
residues from nanotube synthesis (112), lipid peroxidation, mitochondrial dysfunction, 
changes in cell morphology, and platelet aggregation (117). In contrast to this, some reports 
indicate that an inflammatory response does not occur when carbon nanotubes have been 
purified (118). Although the ambiguity of carbon nanotube toxicity and wide array of 
toxicological responses certainly warrants caution, the contradictory data on the toxic effects 
of carbon nanotubes also suggests a need for further research. Therefore, it is believed that 
modification and/or coating of carbon nanotube-based biomaterials would enhance their 
ability as suitable carriers for applications such as drug delivery. For instance, targeted and 
controlled doxorubicin delivery using modified single wall carbon nanotubes have been 
reported (119). In addition, Ren et al. summarized the data on the toxic effects of single-
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walled carbon nanotube with different treatments and suggested on a standard evaluation of 
the effects of carbon nanotube on the cells, organs, or an entire organism (120).  
  Graphene is a material with a one-carbon atom thick, single layer sheet structure that occurs 
in nature in the form of graphite. Graphene can be used for a different range of biomedical 
applications due to its flexible chemical structure blend with its inherent properties. 
Therefore, graphene has become a potential candidate for multifunctional biomedical 
purposes such as biosensors (121, 122) and drug delivery (123). For instance, Hu et al. have 
reported about good antibacterial activity of graphene oxide (GO), recommending its potential 
for drug delivery in ophthalmology application (124). A year later, in 2011, Zhang et al. 
showed that modiﬁed GO could be used for targeted drug delivery and controlled release in 
the tumor therapy (125). Almost at the same time, Yang et al. showed that GO-based 
composites decreased reticuloendothelial system accumulation and remarkably enhanced 
tumor passive targeting effects (126). 
  Recently, Yan et al. investigated the in vitro and in vivo intraocular biocompatibility and 
cytotoxicity of graphene oxide (GO) (127) knowing the fact that eye is a particular organ with 
the presence of the blood−ocular barrier which make it to be important in targeted medical 
therapies such as ocular tumor-related treatments. Therefore, they investigated novel drug 
delivery and controlled release systems in ophthalmology and reported GO has favorable 
biocompatibility for retinal pigment epithelial cells with minimal adverse effects on cell 
viability and morphology in long-term cultures (127).  Furthermore, biocompatibility and 
toxicity of GO on A549 cells has also been evaluated, suggesting that "GO does not enter 
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A549 cell and has no evident cytotoxicity”. Nevertheless, GO could cause a dose- and size-
dependent oxidative stress in cell and a trivial loss of cell viability at high concentrations. 
These data together suggests that overall, GO has an adequate safety profile, for drug delivery 
application, further supported by the positive growth of cells on GO films  (128). 
Although there are studies that address the biocompatibility of graphene, GO and their 
modified versions (129-133), a great deal of research is still required in the near future prior to 
their application in the clinical settings. Furthermore, there is active, ongoing research in the 
role of carbon nanotubes in the delivery of chemotherapeutic agents while limiting systemic 
toxicity (134). 
2.6.2 Polymeric nanoparticles 
Polymeric nanoparticles include synthetic polymers, natural polymers (e.g. proteins), and 
pseudosynthetic polymers (such as synthetic polypeptides are broadly used for drug delivery   
(135). Polymer architecture, composition, backbone stability, as well as water solubility are 
important factors which specify the effectiveness of drug-delivery carriers (136). In this 
section, a selected group of polymeric nanoparticles and dendrimers that have been the most 
commonly used in drug delivery applications are reviewed. 
Currently it is well known that polymer architecture dictates the carrier’s physicochemical 
properties, drug loading effectiveness, drug-release rate and biodistribution (136). 
Polydispersity character of polymer, defined as the heterogeneous combination of chains of 
altering lengths (137), makes them of particular significance for biological properties which 
are molecular mass dependent (138). Polymers have been found to be able to provide a 
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sustained release of encapsulated drugs, protect drugs from the body’s enzymatic and 
degenerative conditions, provide targeting capabilities from a tendency for passive 
accumulation in tumors, and display adjuvant characteristics, meaning that it may help 
prevent subsequent cancer attacks. In addition, they can be used to overcome the poor 
aqueous solubility of certain drugs such as chemotherapeutics (139). Despite all of these 
benefits, polymers are frequently taken up by the immune cells and hence the 
immunocompatibility of these materials must be carefully considered (140). 
It has been reported that polycations may not only be cytotoxic, but can also induce hemolysis 
and complement activation (137). It has also been observed that polyanions are less cytotoxic, 
but still can induce anticoagulant activity and cytokine release (137). Despite these reports, 
there are some reports that address the compatibility of polymers for in vivo applications 
(141). Other studies have shown that nanoparticles made from N-(2-hydroxypropyl) 
methacrylamide (HPMA) were able to mitigate many of the inherently toxic effects of the 
popular anti-cancer drug, doxorubicin (94). Furthermore, it was found that HPMA-bound 
doxorubicin triggered anti-cancer immunity in mice; up to 80% of cured mice were able to 
survive a fatal dose of cancer cells independent of further treatment (142). With regard to 
biocompatibility, evidence suggests that HPMA does not induce a significant response within 
the body, leading researchers to believe that HMPA copolymers are indeed “immunologically 
safe” (94). 
Another type of polymeric-based particle that can be utilized as carriers for drug delivery 
systems is PLGA micro- or nanoparticles (30). These particles are known as clinically proven 
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biodegradable and biocompatible materials (35). One area in which they have been widely 
investigated is in the formulation of the chemotherapeutic drug, paclitaxel (Taxol®) [156]. In 
addition, they represent an innovative approach to adjuvant therapy in vaccination by 
presenting vaccine antigens (31, 34). Studies have reported that these polymeric particulate 
delivery systems (30) can present antigens and trigger specific humoral and/or cellular 
responses (34, 37), highlighting the importance of their size in the resulted outcomes (38, 40). 
For instance, microparticles trigger a humoral-mediated immune response whereas nanosized 
range PLGA particles activate cell-mediate immune responses (41, 42). Not surprisingly, it is 
not easy to predict the phagocytic behavior subsequent to particles' uptake. Nicolete et al. 
produced PLGA nano- and microparticles devoid of any encapsulated bioactive. They then 
examined these particles’ uptake by macrophages as well as their effect in vitro, on the 
production of proinflammatory cytokines, TNF-α and IL-1β (30). They have reported that 
PLGA microparticles of size 6.5 μm, attached to the cell’s surface at 2 and 4 hour incubation 
time and few could be seen inside the cells when compared to nanoparticles (30). Danhier et 
al. have reviewed the beneficial usage of PLGA-based nanoparticles both in vitro and in vivo 
as a therapeutic strategy in different diseases (43); they also reported on the characteristics of 
PLGA-based nanoparticle that makes them a promising candidate for targeted and untargeted 
drug delivery. Poly(lactic acid) (PLA) polymers have also been used in drug delivery (44, 
143); however, due to their slow degradation rate, PLA polymers have not been broadly used, 
compared to PLGA polymers (43). PLA was used for surface modification of organic 
microsphere poly (hydroxyethyl methacrylate) (PHEMA). PLA modified microspheres 
 27 
 
showed better anti-tumor effect as well as increased loading capacity in compare with 
unmodified one (144). 
In general, one of the areas in which more work needs to be done on the development of 
methods for visualization of polymer-based nanoparticles. Even highly sensitive methods 
such as scanning- and transmission electron microscopy are limited in their capability for 
reliable visualization of polymer-based nanoparticles within cells, compelling the need for 
indirect, assay-based methods to examine nanoparticle cellular uptake by phagocytes (11). 
2.6.3 Dendrimers  
Dendrimers are highly branched polymers whose shape, size, branching length, density, and 
surface functionality can be controlled and are well defined (145). Originating from a 
nanosized core, polymeric branches of high specificity are grown outward, forming cavities 
and cages throughout the molecule (116). These channels and closed structures allow for the 
physical entrapment or encapsulation of pharmaceuticals (145). In addition, negatively 
charged drugs may associate themselves through electrostatic interactions with amine groups 
within the dendrite (145). Furthermore, drugs can be chemically attached to surface groups on 
the polymeric structure (116, 117, 145). Dendrimers are susceptive to surface group 
modification and can be tailored to facilitate targeting and improve biocompatibility (116, 
117, 145). For instance, dendrimers with positively charged surface groups are likely to cause 
cell lysis. Dendrimers, like most nanoparticles used for drug delivery, aim to mitigate the 
inherently toxic effects of unbound drugs through targeting and subsequent accumulation in 
tumors; PEGylation abets or assist this process (145). On the subject of toxicity, dendrimers 
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cannot be classified as consistently safe or unsafe. Research suggests that dendrimers must be 
evaluated on a case-by-case basis to classify their particular chemistry’s biocompatibility. A 
lack of research and clinical trial in this field deters generalization regarding safety (117). 
Contrarily, there are known correlations between the properties of dendrimers and their 
functionality and biocompatibility. For instance, size influences both solubility and 
cytotoxicity, and an increase in generation number leads to an increase in both of these 
properties. Lastly, dendrimers, possess antitumor, antiviral, and antibacterial properties, along 
with the capacity to enhance membrane permeability (145). These intrinsic properties have 
sparked interest in dendrimers for bacterial cell killing and trans-membrane transport 
applications (117). 
Micelles act by encapsulating material within its walls. Contrarily, a micelle functions on the 
premise of its amphiphilic monolayer. The inner core of micelles is typically hydrophobic 
enabling successful encapsulation of insoluble drugs, while its hydrophilic outer core renders 
the encapsulated material soluble (113). Self-assembled polymeric micelles have recently 
attracted attention due to their special characteristics, such as high loading capacity and 
improved solubility of drugs, decreased systemic unfavorable effects, enhanced permeability 
and retention (EPR) effect which results in their accumulation at the tumor site, and lastly, 
their possible modification of physicochemical characteristic (33, 146-148). However, with all 
of the advantages, the controlled and smart release of therapeutics from traditional polymeric 
micelles carriers remains a challenge. Currently, nanocarriers are replaced by traditional 
micelle systems, since they can stably encapsulate and release therapeutics at a targeted site as 
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a result of external stimuli such as pH, temperature, redox, and light (149-152). However, 
because of their toxicity, only a small number of them have been moved to  clinical studies 
(153) such as  pH-responsive polymeric micelles (143, 154-158). Therefore, to overcome the 
toxicity of the carriers, polymeric segments composed of polymers with better compatibility 
such as poly (ethylene oxide) and biodegradable polymers like polyesters, are employed to 
form micelles in aqueous solutions. Lee et al. designed and synthesized a new class of 
hyperbranched double hydrophilic block copolymer of poly(ethylene oxide)-hyperbranched-
polyglycerol (PEO-hb-PG) with enhanced biocompatibility, increase water solubility, and 
improved biodegradability after delivery of the drug (153). 
2.6.4  Lipid-based nanoparticles 
Lipid-based nanoparticles such as liposomes represent another category of popular drug-
carrying nanostructures.  Liposomes, not to be confused with micelles which are characterized 
by monolayers, are generally composed of one or more bilayers of an aliphatic lipid molecule 
arranged to form a vesicle. This vesicle formation allows for the encapsulation of drugs, 
vaccines, or other materials within its walls or entrapment within its layers, depending on the 
material to be delivered (116). A number of liposome-based formulations have gained 
approval for the treatment of cancer, infections, and meningitis, with prospective applications 
such as therapeutic vaccines currently under development (159). These include liposomal-
based therapeutics containing the antifungal, amphotericin B (Abelcet®), chemotherapeutic 
drug doxorubicin (Myocet®), immunopotentiating reconstituted influenza virosome 
(Epaxal®) (160). Liposomes have been categorized as those which have been designed to 
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evoke an immune response to a contained antigen and those whose surface have been coated 
with PEG or a similar polymer to mitigate or suppress immune response. In general, 
liposomes with positively charged surfaces are more prone to eliciting an immune response 
than negatively charged or neutral particles (161). A possible downside to liposomes as 
pharmaceutical carriers is their selectivity with respect to functionally compatible drugs. In 
some cases—liposome-entrapped cisplatin, for instance—the particles are unable to release 
the encapsulated drug at a rate sufficient to trigger antitumor activity, despite passive 
accumulation at tumor sites. Nevertheless, doxorubicin-entrapped liposomes of the same 
composition produced effective antitumor properties, corroborating the aforementioned 
selectivity (116).  
Solid lipid nanoparticles (SLNs) mainly consist of solid lipids, which also possess properties 
such as biocompatibility, biodegradability and low-toxicity. SLNs are described as colloidal 
particles of highly purified triglycerides, complex glyceride mixtures, or waxes stabilized by a 
surfactant. These are lipids whose nature allows them to remain solidified at room and body 
temperature (162). When regarded as a drug carrier, SLNs have undergone studies with a 
wide variety of pharmaceuticals ranging in structure and chemical properties (163, 164). 
SLNs have the advantages of both the "soft" drug carriers such as emulsions and liposomes 
and polymeric nanoparticles (14). 
 SLNs are versatile in their methods of drug incorporation; drugs can be loaded into the 
particle’s core or shell, between lipid layers and fatty acid chains, in the particle’s 
imperfections, or dispersed molecularly throughout the particle’s matrix (162). Despite this 
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versatility, SLNs feature a low drug loading capacity. Additionally, SLNs may undergo 
polymorphic transition during storage and administration; this causes gelation, size increase, 
and drug expulsion (162, 163). Undesired lipid-based particles such as micelles and liposomes 
as well as crystalline drug structures may also be formed within the complex, threatening the 
purity of the SLN colloid (163). Conversely, SLNs allow for a variable rate of drug release 
and targeting within the body, provide protection to the encapsulated drug (162), and avoid 
the use of harmful organic solvents, and have potential for large-scale production as a result 
of a streamlined production process. Another advantage lies in SLN composition. Since they 
are made from physiological compounds, metabolic pathways are already in place within the 
body (163). This anticipated biocompatibility has been corroborated through in vitro and in 
vivo studies of SLN toxicity. For instance, tests indicate that SLN are less toxic than 
polymeric nanoparticles (PLA/GA) [178]. Bolus injections in mice also showed no acute 
toxicity as suggested by histopathology (162, 164). Furthermore, it has been noted that SLNs 
are suitable for use in any parenteral application where polymeric nanoparticles are accepted 
(164). Recently, Qi et al. have provided an overview on the absorption, disposition and 
pharmacokinetics of SLNs (165). 
In general, lipid-based nanoparticles are vulnerable to changes in temperature and osmotic 
pressure, among other extrinsic variables. This property, along with their inherent instability 
in biological media, may warrant the need for stability-enhancing alterations such as surface 
polymerization (145). 
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2.6.5  Quantum dots 
 The term “quantum dot” refers to a particular category of nanoparticle characterized 
by a crystalline structure usually composed of a semiconducting material (166). Cadmium 
sulfide and cadmium selenide quantum dots are among the most popular (112). Quantum dots 
(QDs) were discovered in the 1980s and are known to possess unique optical properties that 
make them ideal for imaging purpose (116, 166). In addition, quantum dots may be used for 
cancer detection and therapy (166), and computing applications where light is used to process 
signals (116).  
In a drug delivery scenario, "fluorescent semiconductor nanocrystals", quantum dots, possess 
valuable features, such as small size, flexible surface chemistry, and valuable optical 
properties, making QDs not only to be a good plan for the broad characterization of 
nanocarrier behavior (6) but also allowing their use within almost any nanocarrier- with 
minimal effect on overall characteristics- and drug release at both cellular and systemic levels 
(167). Like all nanoparticles proposed for use in the human body, quantum dots are being 
tested for biocompatibility. The innate properties of the material will determine factors such 
as adsorption, distribution, metabolism, excretion, and toxicity, as well as the environmental 
conditions in which the particle is placed. Studies have shown that quantum dots themselves 
may induce toxic effects such as damage to plasma membranes, mitochondria and nuclei. For 
this reason, and for the purpose of targeting, these nanoparticles are often surface-coated; this 
may, however, induce additional toxicity. Furthermore, it was found that the quantum dot’s 
toxicity is influenced not only by its surface chemistry, but also by its core material (117). 
However, appropriately coated and passivated QDots do not show acute toxicity in vivo and in 
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rhesus monkey (168) regardless of the possible release of toxic chemicals such as cadmium, 
Cd (6) and production of reactive oxygen species (5). Modified quantum dots would permit 
brief nanocarrier screening without non-specific unfavorable effects (167).   
   P. Zrazhevskiy discussed about reducing long-term QDot toxicity (168). Such properties 
would have made quantum dot platform to be a potential candidate for clarifying, in vivo and 
in vitro, mechanisms of nanoparticle targeting, intracellular uptake, and trafficking (167). This 
in turn would ease assessment of the nanocarrier behavior in a range of drug delivery 
applications as well as contribute for design of novel nanotherapeutics, such as "NP-based 
antigen delivery vectors for immunotherapy" (167). As toxicity is inherent to traditional 
quantum dots, the search for less harmful materials is ongoing and of great interest (166). 
2.6.6 Metallic nanoparticles 
Metallic nanoparticles hold potential for use in both diagnostic imaging and targeted drug 
delivery. These nanoparticles are often delivered in solid colloidal form and aim to increase 
the therapeutic index of anticancer drugs through passive or active targeting while mitigating 
toxic effects by limiting drug exposure to healthy cells and tissues. Metal-based particles hold 
the potential to carry large drug doses as well as increase its circulatory half-life. 
Additionally, surface modification is possible due to a large surface area-to-volume ratio (6), 
the effects of which have been discussed in previous sections. 
 The use of colloidal gold in medicine can be traced back to the 1920s for the treatment 
of tuberculosis (112). Since then, colloidal gold nanoparticles have been widely researched as 
drug and gene delivery vehicles. They can be synthesized in a variety of forms (e.g. rod, dot) 
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(117) and are easily detectable within micromolar concentrations, warranting their use in 
imaging applications (112). With regard to biocompatibility, cells have been shown to intake 
gold nanoparticles without cytotoxic effects (112, 118). Lai et al. demonstrated a median 
lethal dose (LD50) of over 5 g/kg of body weight using a nanogold suspension with a particle 
diameter of 50 nm (169). Metallic nanopoarticles, including colloidal gold, continue to be 
actively investigated for the purpose of drug delivery and other applications. Research in this 
field is expected to grow over the next few decades (6). 
2.7 Major Obstacles To Effective Drug Delivery 
In the last several years, drug delivery research has witnessed remarkable growth due to the 
utilization of nanoparticles as “controlled release reservoirs” for the targeted delivery of drugs 
for combating many diseases (145). Evidence has shown that several different nanoparticles 
have been used as a carrier for drug delivery systems (145, 157, 170). The problem remains, 
however, that nanoparticles’ applications are still limited mainly by their unknown 
biocompatibility properties, which may cause their quick removal by the immune systems. 
Recently, the knowledge about nanoparticle interaction with components of the immune 
system has increased. But, still many questions such as particle immunomodulatory effects 
(immunostimulation and immunosuppression) need to be completely addressed. 
Understanding the mechanisms behind these different outcomes will allow prediction of the 
relationship between nanostructures and their interactions with the biological milieu. Indeed 
the ability of a nanoparticle to evade immune recognition represents an area of interest in the 
field of drug delivery. One of the promising approaches towards this goal has been through 
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the development of the self-assembled peptide nanomaterials due to their perceived 
biocompatibility and structural diversity. As a result, they have become attractive as building 
blocks for a variety of applications such as materials science, tissue engineering, 
bioengineering, and of particular interest to this research, drug delivery (27-31, 33-36, 112). 
The following two sections review the concept of molecular self assembly and one class of 
self assembling peptides, ionic complementary peptides, respectively.  
2.8  Molecular Self-assembly 
 “There's Plenty of Room at the Bottom” is a lecture given on December 29, 1951 by physicist 
Richard Feynman who predicted the potential of atomic/molecular engineering and inspired 
the conceptual development of the nanotechnology field, which occurred decades later. 
Nowadays, nanotechnology is mainly based on “bottom-up” atomic/molecular development 
for chemical and physical construction of stable nanostructures or supramolecules. The key 
component of this “bottom-up” advance is molecular self-assembly. As a result, in recent 
years, molecular self-assembly has become a useful tool for expanding the production of new 
biomaterials. The self-assembly of biomolecules is a well-known phenomenon in biology, 
encompassing self-complementary DNA double-helix annealing and protein aggregation. 
Self-assembly in the most basic form consists of the "spontaneous organization of molecules 
under thermodynamic equilibrium conditions into structurally stable arrangements by the 
driving force of non-covalent interactions, including hydrogen bonds, electrostatic interaction, 
and van der Waals interactions" (171) .  
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Recently, short peptides have allowed material scientists to design functional 
nano/microstructures for different applications based on their self-assembly capabilities. A 
promising class of self-assembling peptides is the self-assembling ionic-complementary 
peptides (29, 30). 
2.9 Ionic- Complementary Peptides 
 This class of peptides was discovered twenty years ago at MIT and has been used in molecular 
medicine and nanobiotechnology. As a result, now, this class of peptides has the potential to be 
used as carriers for drug delivery. Their properties, including alternating hydrophobic and 
hydrophilic amino acids and stable β-sheet nanofibers in aqueous solution, give them 
potential to encapsulate hydrophobic chemotherapeutics such as the anticancer drug 
pirarubicin. Three important features of ionic-complementary peptides are charge distribution, chain 
length as well as amino acids replacement (172).  
The molecular structure of ionic-complementary peptides is characterized by an alternating 
arrangement of negatively and positively charged residues that must follow certain patterns. 
The three most simple and most studied types of charge distribution that are known 
facilitators of self-assembly are type I (−+ or +−), type II (−−++ or ++−−) and type IV 
(−−−−++++ or++++−−−−). Such ordered charge distribution promotes molecular self-
assembly and results in nanostructure stabilization of ionic complementary peptides. 
Therefore, ionic-complementary peptides have several important features which make them 
promising molecules for fabrication of materials that can form stable nano/microstructures 
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(74, 173). The following section reviews the ionic-complementary self-assembling peptides 
which will be used in this research. 
2.10  EAK, EK and AC8 Peptides 
The first member of the ionic-complementary peptide family is EAK16-II (EAK). This 
peptide is a 16 amino acid (AEAEAKAKAEAEAKAK), which has been studied since 1992 
(174, 175). EAK was initially found in a region of alternating hydrophobic and hydrophilic 
residues in zuotin. Zuotin is a yeast protein that was initially identified for its affinity to left-
handed Z-DNA. The EAK peptide consists of only three amino acids namely alanine (A), 
glutamine (E), and lysine (K). 
   EK8 peptide, as another member of ionic-complementary peptides, is an 8 amino acid  
peptide (EEKKEEKK), consisting of two ionic amino acids glutamine and lysine with 
possible enhanced water solubility and stable self-assembly. This peptide can help to 
investigate the effect of length of backbone, from 8 to 16 amino acids, and the presence of 
hydrophobic residue alanine while keeping the same charge distribution in compare with 
EAK. 
   The AC8 peptide consists of eight amino acids and contains a hydrogen bonding pair (QN), 
one ionic pair (EK) and four hydrophobic phenylalanine (F) side chains. Hydrophobic amino 
acids were incorporated to create a hydrophobic interior for encapsulation and stabilization of 
hydrophobic compounds such as anticancer drugs for drug delivery purposes. 
However, because of limitations, when using such a self-assembling system for medical 
applications, a new class of ionic-complementary peptides, called amino acid pairing 
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peptides, has been designed (176). These limitations include but not limited to the fact that 
ionic complementarily has to be ensured which in turn would limit the peptide sequence 
design possibilities.  
2.11 Amino Acid Pairing Peptide  
The principle of amino acid pairing (AAP) peptides is that any self-assembling peptide can be 
designed through the pairing any of the three side chain interactions: hydrophobic, ionic, and 
hydrogen bonding among amino acid pairs. By this strategy, a large library of peptides can be 
made. Here, in this thesis, self-assembling peptides designed through the pairing of the side 
chains will be designated as “AAP peptides”. For example, in the case of AC8 (AAP8) with 8 
amino acid residues, it utilizes the, three side chain interactions which would assist peptide 
association in addition to the backbone hydrogen bonding to form stable β-sheets. The 
specific side chain interactions in AAP8 are as follows: hydrophobic, electrostatic, and 
hydrogen bonding. The peptide contains four hydrophobic phenylalanine (F) side chains 
which provide strong hydrophobic interactions assisted by π stacking to stabilize the 
assembled nanostructures as well as to create a hydrophobic region to carry hydrophobic 
compounds for drug delivery applications. It also contains a hydrogen bonding pair (QN) 
which can increase the overall hydrophobicity and should not be significantly affected ,by 
solution pH and charge screen agents (i.e., salts) compared with the ionic pairing by K and E. 
An ionic pair (EK) which provides reasonable water solubility has also been incorporated into 
AAP8. The non-charged hydrogen bonding pair QN together with the ionic pair EK is 
expected to further enhance the stability of the assemblies. Through this design, the AAP8 
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peptide can self-assemble into β-sheet rich nanofibers with the potential to carry hydrophobic 
drugs (176).  
Therefore, with respect to their advantages and potential as drug carriers, the necessity of 
understanding biocompatibility of these peptide based nanoparticles is undeniable, as 
bioincompatibility is the one drawback these systems can face. Hence, the study of this 
nanoparticle’s interactions with blood components and immune cells, as well as its toxic 
effects, should be seriously considered in order to translate the use of peptide based 
nanoparticles from research to preclinical or clinical studies.  
2.12 Regulatory Agencies 
It was previously mentioned that drug delivery systems, no matter how attractive they seem, 
hold no weight unless they are considered adequately biocompatible. The same is true without 
approval from a regulatory agency such as the FDA or the European Medicines Agency 
(EMEA). These two qualifiers are often a function of one another. While existing guidelines 
awkwardly govern the use of nanomedicine, additional regulations are required to address the 
properties specific to nanomaterials, be it immune system or surface chemistry modification. 
As novel applications of nanotechnology in medicine and requests for approval continue to 
flow from research institutes worldwide, the need for nanotechnology-specific regulatory 
guidelines is made even more obvious. Regardless, standardized guidelines have yet to be 
established. On the whole, continued in vitro and in vivo testing is required to build a database 
of knowledge on the subject of nanoparticle biocompatibility. Only then, after sufficient 
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scientific evidence, will regulatory agencies put forth the effort of developing new guidelines 
(109).  
2.13 Conclusions 
This chapter was intended to provide an overview of recent findings of biocompatibility for 
several different nanoparticles. Biocompatibility is a word that is used broadly within 
biomaterial science, but there is still a great deal of uncertainty about its meaning as well as 
about the mechanisms that collectively constitute biocompatibility. Effective and 
biocompatible drug delivery systems based on nanoparticles as a carriers has been the dream 
of scientist for many years. Although we are still far from our ultimate goal of biocompatible 
drug delivery, progress which points to the growing importance of this research area in related 
to human health has been made. As biomaterials are being used in increasingly diverse and 
complex situations, with applications now involving tissue engineering, invasive sensors, 
RNA interference (siRNA) delivery and of particular interest to this thesis, drug delivery, 
uncertainty over the mechanisms of, and conditions for, biocompatibility is becoming a 
serious obstacle to the development of new techniques. 
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Chapter 3* 
In Vitro Biocompatibility of theAC8 peptide and its potential use as 
a drug carrier 
3.1 Introduction 
Since the first application of biomaterials as conventional therapeutics, there has been 
tremendous interest in materials capable of sustained macromolecular delivery (177, 178). As 
research has progressed, modern pharmacotechnology has evolved such that the main goal 
now is to improve the therapeutic efficacy and controlled targeted release of drugs by using a 
variety of nanoparticles as carrier systems (179-185). Recent years have witnessed a  
expansion of the use of nanoparticles for drug delivery applications (186-189). Given their 
advantages and potential, the necessity of understanding biocompatibility of nanoparticles is 
undeniable, as bioincompatibility is the one drawback these systems can face. Hence, the 
study of nanoparticle interaction with blood components and immune cells, as well as its toxic 
effects, should be  considered in order to translate the use of nanoparticles from research to 
preclinical or clinical studies. Haemolysis, immune system responses such as complement 
activation, and cytotoxicity are the main concepts considered for nanoparticle 
biocompatibility.  
                                                     
* This chapter is based on submitted paper Sheva Naahidi, Yujie Wang , Man Zhang, Rong Wang, Mousa Jafari ,Yongfang 
Yuan *, Brian Dixon,  P. Chen**, Evaluation of Biocompatibility of the AC8 peptide and its potential use as a drug carrier 
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 Erythrocytes occupy a larger volume fraction of the blood than leukocytes and lysing of 
excessive number of red blood cells can lead to anemia; therefore, in vitro examination of 
haemolysis is an instrumental part of preclinical studies of nanoparticles (190). Additionally, 
recent ongoing research, for instance work by Liangfang Zhang’s group, has focused on using 
or mimicking erythrocytes as a drug delivery system (191). A number of mechanisms for 
drug-mediated haemolysis have been recommended, yet the true mechanism is yet to be 
identified.  It is now well known that surface properties (especially surface charge) play an 
important role for nanoparticles and can directly damage erythrocyte membranes. For 
instance, in the presence of certain concentrations of unprotected primary amines (positive 
charge), red blood cell damage was observed on the surface of poly-amidoamine, carbosilane, 
polypropylene imine, and poly-lysine (115, 192-196).  
Another important aspect that greatly affects the delivery of drugs is their uptake by 
immune cells and clearance from intended target sites. It is now well known that the 
complement system, which plays a crucial role in this process, consists of more than 20 
different plasma proteins and protein fragments as inactive zymogens in the blood (197, 198). 
Complement system activation results in the activation of the cell-killing membrane attack 
complex (MAC) (199). There are three major complement pathways that may become 
activated: the classical, alternative and lectin pathways. One pathway that was recently 
discovered but not fully understood is the ficolin innate immune recognition (200). Ficolins 
are oligomeric defense proteins that bind to acetylated molecules as well as neutral 
carbohydrates that trigger the lectin pathway (201, 202). In the classical pathway, the C1q 
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protein recognizes and attaches to antibody bound to the pathogen, C1r and C1s, through 
electrostatic and hydrophobic interactions. The lectin pathway is activated via mannan-
binding lectin (MBL) binding to neutral sugar residues, while the alternative pathway is 
started by C3b protein binding to the hydroxyl or amino groups on a pathogen’s surface (203-
205). Recent studies have recognized the importance of nanoparticle surface charge in 
activation of the complement system. For instance, polypropylene sulfide nanoparticles, lipid 
nanocapsules, cyclodextrin-containing polycation-based nanoparticles and polystyrene 
nanospheres have shown that charged nanoparticles activate the complement system more 
efficiently than neutral nanoparticles (206-208).  
Indeed the ability of a nanoparticle to evade immune recognition represents an area of 
interest in the field of drug delivery. One of the promising approaches towards this goal has 
been through the development of the self-assembled peptide nanomaterials due to their 
perceived biocompatibility and structural diversity. A new, promising class of self-assembling 
peptides is the self-assembling ionic-complementary peptides (209, 210). The self-assembling 
peptide AC8 nanoparticle is a short (eight amino acids long) peptide with the sequence Ac-
FEFQFNFK-NH2 which self-assembles into β-sheet-rich nanofibers. The schematic of the 
molecular structure of this peptide is shown in Figure 3-1.  
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Figure 3-1 Schematic of the chemical structure of AC8. Abbreviations: AC8: Ac-FEFQFNFK-NH2. 
The capability of the AC8 to stabilize the hydrophobic anticancer drug ellipticine in 
aqueous solution has been already investigated (211). However, the biocompatibility 
properties of the AC8 have not yet been explored, which is a necessary first step in systematic 
drug delivery application.  
Here,  the systematic investigation of the in vitro biocompatibility and 
immunocompatibility properties of self-assembling ionic-complementary peptide AC8 was 
reported. The potential ability of this peptide to be utilized as a carrier for the delivery of the 
hydrophobic anticancer drug pirarubicin was demonstrated. Nuclear uptake of AC8-
pirarubicin complexes by A549 cells was shown by confocal microscopy. Finally, it 
wasdemonstrated that AC8 peptides had favorable in vitro biocompatibility.  
3.2  Materials and Methods 
3.2.1 Peptide preparation 
The peptides AC8 (purity>98%) were purchased from CanPeptide Inc. (Montreal, Canada) 
and used without further purification. The primary structure of AC8 is FEFQFNFK and its 
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secondary structure is beta-strand. The N-terminus and C-terminus of the peptides were 
protected by acetyl and amino groups, respectively. AC8 was characterized for its self-
assembling properties in aqueous solution at 0.5 mg/ml and a molecular weight of 1147.31 
g/mol was confirmed by mass spectroscopy. Fresh aqueous peptide solutions was prepared by 
dissolving peptide powder in pure water (18.2 MV, Milli-Q A10 synthesis) at specified 
concentrations, followed by sonication for 10 min.  
3.2.2 Cytotoxicity Assay 
Non-small cell lung carcinoma cells A549 were obtained from American Type Culture 
Collection (ATCC, Manassas, VA, USA). The MTT ((3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide, a tetrazole) cell proliferation and viability assay kit (TOX1 
from Sigma-Aldrich, Oakville, ON, Canada) was used to perform cytotoxicity assays. A549 
cells were seeded onto 96-well plates at a density of 104 cells per well and treated 24 h later. 
20µL of the AC8 peptide was diluted in 180µL of growth media (DMEM containing 10% 
FBS) and added to each well. DMEM served as the blank and untreated cells served as the 
control. The plates were incubated for 24 h and 48 h prior to performing the cell viability 
assay. Then, 100 µL of MTT substrate was added to each well and incubated for an additional 
4 h at 37°C in the dark before addition of 100 µL solubilization. Absorbance was measured at 
a wavelength of 570 nm using a microplate reader (model 550; Bio-Red, CA, USA). Cell 
survival was expressed as a percentage of the absorbance value determined for control 
cultures using the following calculation: Viablility = (sample absorbance – blank absorbance) 
/ (negative absorbance - blank absorbance). 
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3.2.3  Haemolysis Studies 
Haemolysis experiments were carried out by using approximately 5mL of fresh human 
anticoagulated blood. The blood was centrifuge at 1500rpm for 10 minutes and washed three 
times by adding Dulbecco’s Phosphate Buffered Saline (DPBS). After washing, red blood 
cells (RBCs) were isolated, suspended in DPBS to the original volume and then diluted 
further with DPBS to make a 5% hematocrit solution. Varying concentrations of the peptide 
in 800 µl of DPBS were added to the 200 µl of RBCs. DPBS and water served as positive and 
negative controls, respectively. After incubation for two hours all of the samples were then 
centrifuged after which the supernatant was removed and placed into a clean cuvette. 
Subsequently, the absorbance was measured at 541nm. The haemolysis in the water solution 
was considered to be 100% while the hemolysis in the DPBS solution was taken as 0%. The 
results were thus expressed as percentage hemolysis. 
3.2.4  Complement system activation studies 
In order to determine the amount of complement activation caused by the AC8 peptides in 
vitro, the active forms of four complement products (C4d, SC5-b9, Bb and MBL) were 
analyzed using enzyme-linked immunosorbent assay kits from Quidel Corp, (San Diego, CA, 
USA) and ALPCO Diagnostics kit (Salem, MA, USA). Peptide samples were incubated with 
human serum at a volume ratio of 1:5 in a shaking incubator (100 rpm) for 60 minutes at 
37°C. Three time points were measured (1-3 hours); However, there was no increase at later 
time points. The samples were then diluted further with Sample Diluent according to the 
manufacturer’s instructions to determine the amount of C4d, Bb, SC5b-9 or mannan-binding 
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protein that was formed by the complement system during the incubation. The C4d 
immunoassay measures the amount of active C4 fragments present in human serum which 
indicates the activation of the classical pathway. The Bb Plus immunoassay assesses the 
amount of Factor B cleavage that occurs, providing a measure of the activation of the 
alternative pathway. SC5b-9 measures the Terminal Complement Complex which is formed 
by either the classical, alternative or lectin pathways. MBL is the protein which indicats that 
the lectin pathway has been activated.. Zymosan (a known complement activator) was used as 
a positive control and untreated human serum was used as a negative control; both were 
assayed in the same way as all the other samples. The results were then read at 450 nm 
(FLUOstar OPTIMA, BMG, NC). Standard curves were made for quantification of 
complement activation products by using the assigned concentration of each individual 
standard supplied by the manufacturer and validated. The slope, intercept and correlation 
coefficient of the derived best fit line for SC5b-9, Bb, C4d and MBL standard curves were 
within the manufacturer’s specified range. The efficacy of the treatments was determined by 
comparison with baseline levels using the paired t-test. 
3.2.5  Anaphylotoxin studies 
In order to assess the amount of C3a and C5a, samples were incubated with human serum in a 
1:5 ratio in a shaking incubator (100 rpm) for 60 minutes at 37°C. The samples were then 
tested according to manufacturer’s instructions for the enzyme-linked immunosorbent assay 
kits from Quidel Corp. (San Diego, CA, USA). The results were then read at 450 nm 
(FLUOstar OPTIMA, BMG, NC). Since C3a is factor produced by the activation of the 
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classical, alternative or lectin complement pathways, Zymosan, from Quidel Corp. (San 
Diego, CA, USA), was used as the positive control and human serum was used as the negative 
control. 
3.2.6  Statistical analysis 
Statistical analysis was carried out using ANOVA or Student’s t-test where applicable. In 
vitro experiments were repeated at least three times. Differences were considered significant 
when the p value was less than 0.05. 
3.3  Results and Discussion 
3.3.1  Cytotoxicity of peptide 
The cellular toxicity of AC8 was determined by MTT assay as shown in Figure 3.2  The 
cellular viability in the high AC8 dose group (0.1 mg/mL) at both 24 and 48h time intervals 
were significantly lower than the non-treated cell group (0.88±0.03 and 0.62±0.03, 
respectively). In addition, the cellular viability of AC8 in the low dose group (0.025 mg/mL) 
at 48h was also significantly lower than the non-treated cell group (0.76±0.07). However, the 
therapeutic dose of AC8 at 24 hour did not show any impact on cellular viability. These 
results suggested that AC8 at therapeutic concentration was biocompatible whereas at high 
concentrations it significantly affected cell viability of A549 cells compared with non-treated 
cells. Although with increasing incubation time and dose, the anti-proliferative effect of AC8 
became more significant, Figure 3-2, it is safe in low dose as a drug carrier.  
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Figure 3-2 Cytotoxicity of AC8 was measured against the lung cancer cell line A549. Three independent 
experiments were performed for each data point. AC8H represent group treated with high AC8dose (0.1 
mg/mL) and AC8L represent group treated with low AC8dose (0.025 mg/mL). Error bars represent 
standard error of mean (SEM) of three independent experiments*: p<0.05 VS non-treated group in 24 
hours; #: p<0.05 VS non-treated group in 48 hours. 
 
Although, it is preferable for carriers in a drug delivery system to have inert biological 
activity, it would be of interest if AC8 would contain anti-tumor activity similar to the drug 
for pharmacological research. In this work, it was concluded that in addition to its safety as a 
drug carrier, when overdose, AC8 demonstrated anti-tumor activity- at high doses. 
3.3.2 Haemolysis 
Hemolysis is the breakage of the RBC’s membrane, causing the release of hemoglobin and 
other internal components into the surrounding fluid; therefore, it is a crucial factor in 
evaluating the biocompatibility of biomaterials. It is also a common occurrence seen in serum 
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samples and may compromise the laboratory’s test parameters. When determining the 
hemolytic activity, a ratio of 5% or less haemolytic activity is considered biocompatible 
(212). In the present study the haemolytic potential of untreated human blood with the self-
assembling peptide AC8 was investigated to see the possible hemolytic effect on RBC. 
 
 
Figure 3-3 (A) Haemolytic activity of AC8. Error bars represent SEM of three independent experiments 
(B) Detection of RBC aggregation by light microscope (400X). AC8H represent group treated with high 
AC8 dose (0.1 mg/mL) and AC8L represent group treated with low AC8dose (0.025 mg/mL).  
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As shown in Figure 3-3A, the results of the in vitro hemolytic assay showed that the self-
assembling peptide AC8 has no hemolytic activity within the therapeutic range of 
concentrations. However, at concentration as high as 0.1mg/ml, AC8 showed some 
haemolytic activity. Nevertheless, in terms of aggregation, there was no RBC aggregation 
with the AC8 peptides, neither at high nor low concentration, Figure 3-3B. Therefore, while 
both monomers and polymers are present in samples aggregates are not. This is important 
because aggregates are probably more likely to induce immune responses if they get inside 
the cell – HSPs will bind them and induce responses. These observations confirm that AC8 is 
not hemolytic and do not cause erythrocyte aggregation within the therapeutic range of 
concentrations.  
3.3.3 Complement system activation  
The complement system, as one of the key effector mechanisms of humoral and innate 
immunity, consists of several, generally inactive, serum and cell surface proteins which are 
activated only under particular conditions to generate products that mediate a variety of 
effector functions. The classical pathway uses a C1 plasma protein to detect IgM, IgG1 or 
IgG3 antibodies attached to the surface of a microbe or other structures. The alternative 
pathway is elicited by the spontaneous cleavage of the thioester bond in C3 (“C3-tickover”) or 
when the internal thioester bond in the α-chain of nascent C3b go through nucleophilic attack 
by the direct detection of a microbial surface structure rich in nucleophilic groups 
(particularly hydroxyl- and amino-rich surfaces) (213, 214). The lectin pathway is activated 
by an MBL plasma protein which identifies terminal mannose residues on microbial 
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glycoproteins and glycolipids. Therefore, not surprisingly, the majority of the consequences 
of complement activation result from the pharmacological effect of some of the activated 
components. Accordingly, clarification of the potential to activate complement can be used as 
one decisive factor in testing the biocompatibility of a variety of nanoparticles. Different 
types of nanoparticles, especially polymers, have been used in medicine for targeted or 
controlled release of various drugs and diagnostic agents, of which many have been assessed 
for complement activation (215-219).  
Here,  the effect of AC8 peptide on the three major complement pathway is reported. After 
incubation with human serum, Bb and C4d concentrations were measured to assess the 
complement system activation via alternative and classical pathways. As shown in Figure 3-
4A, complement activation via the classical pathway was not observed for AC8 peptides. 
Classical activation can be due to binding of C1q (main recognition unit of classical pathway) 
to the peptide via electrostatic or hydrophobic interactions (220).   
The MBL pathway was assessed using a kit that measures the amount of functional MBL 
oligomer remaining in the solution. When the pathway is activated, the oligomer will bind to 
the surface of the invading particle rendering it dysfunctional. After incubating the samples 
with human serum for an hour to allow time for the oligomer to bind to the surface of the 
peptides and peptide complexes, the amount of remaining functional MBL oligomer was 
measured. Figure 3-4C shows that for the positive control, there is very little functional MBL 
oligomer remaining and for the negative control all the functional MBL oligomer remains. 
For our samples, there is activation for AC8 peptides, although it is less than the positive 
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control, Figure 3-4C. While there was lectin pathway activation; nevertheless, it did not reach 
the “threshold” level of activation required for the next step of complement activation because 
there was no significant Bb activation, Figure 3-4B.  
 
Figure 3-4 Complement activation of classical (A), alternative (B), and mannan binding lectin (C) 
pathways of the AC8s (60 µg/ml). Error bars represent SEM of three independent experiments. * denotes 
statistically significant difference compared to the negative control (human serum), as determined by two-
sample t-test (p<0.05). Abbreviations: SEM: standard error of mean. 
3.3.4 Anaphylotoxin activation 
Upon either classical, lectin or alternative pathway activation, the C3 protein is split into two 
fragments, C3b and a potent anaphylotoxin C3a. Therefore, the presence of C3a in a test 
sample proves that peptide nanoparticles can activate complement by one or both pathways. 
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On the other hand, C3b can participate in the formation of a new enzyme, the C5 convertase, 
which cleaves C5 to C5b which drives the rest of the common terminal pathway, and C5a, 
also a very potent anaphylotoxin. One outcome of C5b production is cell killing by forming a 
MAC. However, a large amount of the C5b generated with in vitro samples is diverted to the 
fluid phase by reacting to S protein to form soluble SC5b-9 which can be measured as proof 
of terminal pathway activation. An important point is that for each mole of detected SC5b-9, 
an equal number of moles of C5a are generated. C5a is a small, sticky and exclusive molecule 
with a short half-life. In contrast, SC5b-9, as a marker for C5 cleavage, is an extremely stable 
soluble macromolecular complex and can be used as a marker for C5a anaphylotoxin 
generation. Accordingly, to further assess the in vitro extent of NP-induced activation of 
complement, SC5b-9, C3a and C5a were evaluated. SC5b-9 concentration was measured after 
incubation with human serum.  
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Figure 3-5 (A) Complement activation of the terminal pathway by the AC8 (60 µg/ml). Bars represent the 
mean concentration of SC5b-9, a biomarker of C5a through both the classical and alternative pathways. 
(B) Anaphylatoxin C3a assay comparing the concentration of C3a in AC8 treated samples, and positive 
(Zymosan) as well a negative control (Human serum). (C) Anaphylatoxin C5a assay comparing the 
concentration of C5a in AC8 treated samples, and positive (Zymosan) as well a negative control (Human 
serum). Error bars represent SEM of three independent experiments. * denotes statistical significance 
compared to the negative control, as determined by two-sample t-test (p<0.05). Abbreviations: SEM: 
standard error of mean. 
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As shown in Figure 3-5A, it was found that AC8 formulations did not activate the terminal 
pathway of complement system with respect to human serum (negative control) and were 
significantly less than Zymosan (positive control). Similar results were observed, as expected, 
in regards to C3a and C5a anaphylotoxin, Figure 3-5B, C. In summary, the ionic, 
complementary self-assembling peptide AC8 did not activate the complement system in vitro 
highlighting the potential of this peptide to be used as a drug delivery system.  
3.3.5 Confocal microscopy 
Confocal fluorescent microscopy confirmed the nuclear uptake of anti-cancer drug pirarubicin 
(tetrahydropyranyladriamycin) when complexed with the peptides as shown by its co-
localization with the nucleus (Figure 3-6 A-C). 
 
 
Figure 3-6 Confocal microscopy of A549 cells treated with AC8-pirarubicin complexes confirming the 
presence of pirarubicin inside the nucleus. Violet nucleus (C) implies the co-localization of pirarubicin 
(red) (B) and DAPI (blue) (A) at the same confocal layer. Abbreviations: DAPI: 6-diamidino-2-
phenylindole. 
Pirarubicin's hydrophobicity and fluorescence characteristics make it a good candidate to be 
used for our drug delivery system using AC8 as its carrier. The peptide mediated the nuclear 
uptake of pirarubicin, represented as violet areas (merged), as the result of localization of 
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pirarubicin (red) in stained nuclei (blue). It is worth mentioning that the range of 
concentrations used in all of conducted experiments highly exceeds the dose considered for 
therapeutic purposes (i.e. < 2.5μg/ml). 
3.4 Conclusions 
The in vitro biocompatibility of the complementary, ionic self-assembling peptide AC8 was 
systematically investigated. It was found that the AC8 peptide showed potential in vitro 
compatibility in terms of cytotoxicity, haemolytic activity, RBC aggregation and 
anaphylotoxin as an end result of complement activation. The AC8 peptide itself could 
significantly inhibit the proliferation of A549 cells at a high dose. Hence, AC8 could be 
considered as a potential anti-tumor drug in the future. It is worth mentioning that good 
nuclear uptake of pirarubicin was also demonstrated using AC8 as a carrier.  
The in vitro data presented here is helpful in predicting the effects of AC8 peptide in vivo. 
Indeed, as more mechanistic studies take place in this regard, a more complete picture can be 
proposed for the use of AC8 in drug delivery. Based on all of in vitro data presented here, the 
AC8 peptide would be a favorable drug delivery vehicle - if treatment adheres to the 
recommended therapeutic concentration- for future studies.  
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Chapter 4* 
Immuno- and hemocompatibility of amino acid pairing  
peptides and potential use for anticancer drug delivery 
4.1 Introduction 
One of the goals of biomaterial research is to develop novel, yet safe,  therapeutics and therefore 
materials possessing the ability for sustained macromolecular delivery have been extensively studied 
(221, 222). Modern pharmacotechnology now seeks to improve the therapeutic efficacy and controlled 
targeted release of drugs by using a variety of nanoparticles as carrier systems (181, 182, 185, 223, 
224). Given their advantages and potential in other aspects of drug delivery, the necessity of 
understanding biocompatibility of nanoparticles is unquestionable. . Indeed, a detailed assessment 
of the biocompatibility of nanoparticles is crucial for the safe development of therapeutic 
carriers, to identify the smallest possible defence reaction in the recipient. In order to fulfill 
these, experimental studies of haemolysis, complement activation, and cytotoxicity on human 
blood are required to determine a full picture of an in vitro biocompatibility study (225).  
Then, all of these data together can rationalize whether in vitro data are related to effects 
would be observed in vivo and how to translate these data into a predicted response in human 
patients. As a result, these experiments are critical and essential towards our efforts to develop 
a novel nanomedicine approaches to effective delivery system. Indeed, as more mechanistic 
studies are taking place in this regard, a more complete picture can be proposed which 
assumes paramount importance. 
                                                     
* This chapter is based on a paper Sheva Naahidi, Mousa Jafari, Megan Logan, Faramarz Edalat, Brian Dixon, P. Chen* 
Immuno- and hemaocompatibility of  amino acid pairing  peptides and potential use for anticancer drug delivery 
(submitted) 
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(225). For instance, some studies have shown that surface properties of nanoparticles can directly 
damage erythrocyte membranes and the presence of surfactants increases the amount of haemolysis; 
while modification with poly (ethylene glycol) (PEG) or PEGylation decreases the amount of 
haemolytic activity (197, 229).  Another important aspect that greatly affects the application of 
nanoparticles as intravenous drug delivery platforms may rely on avoiding fast elimination 
from the systemic circulation by cells of the immune system. As soon as nanoparticles enter 
the bloodstream, they meet a complex environment of plasma proteins and immune cells. 
Nanoparticle uptake by the immune cells- can be facilitated by the adsorption of opsonins to 
the particle’s surface - may occur both in the blood stream  and in tissues through various 
pathways. This uptake can make a nanoparticle to be routed away from the site of its intended 
application and  significantly decrease the number of nanoparticles available to reach the 
target site. Consequently,  the efficacy of the drug will be efficiently dropping. As such, 
understanding nanoparticle immunocompatibility is an important step during the initial 
characterization of nanomaterials. As a first step to validate the use of any nanoparticle to be 
used as a carrier for drug delivery system, their interaction with a part of the human immune 
system, complement, has to be explored. 
The complement system is part of the human innate immune system and consists of  
different plasma proteins and protein fragments as inactive zymogens in the blood (225). The 
complement system activates- by three major complement pathways- when zymogens 
stimulate receptors resulting in activation of the cell-killing membrane attack complex (MAC) 
(199).   Salvador et al. reported that non-functionalized, high pressure carbon monoxide 
single-walled and double-walled carbon nanotubes activate the complement system (204), but 
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those whose surface is functionalized with PEG can depress or prevent such immunological 
responses. In contrast, other types of PEGylated nanoparticles such as clinically approved 
formulations of PEGylated liposomes (Doxil®) have shown that steric hindrance of PEG may 
not hinder complement activation and fixation (94, 236, 237). For instance, use of Doxil® in a 
large number of human recipients has caused immediate acute pseudo-allergic reactions and 
cardiopulmonary distress. These conditions are related to generation of anaphylatoxins C3a 
and C5a, which in turn caused release of thromboxane A2 and other inflammatory mediators 
from immune cells (238).  
Indeed the construction of nanoparticles that are documented as self or there is a lack of immune 
recognition, represents a major area of interest in the field of drug delivery. 
  One of the promising approaches towards this goal has been through the development of 
self-assembled peptide nanomaterials which have gained a great amount of attention due to 
their possible biocompatibility and structural diversity. As a result, they have become 
attractive as building blocks for a variety of applications such as materials science, tissue 
engineering, bioengineering, and of particular interest to this thesis, drug delivery (239-248).  
Recently, a new class of self-assembling peptide, the amino acid pairing peptide (AAP8) 
nanoparticles has been described (249). AAP8 is a short (eight amino acid) peptide with the 
sequence Ac-FEFQFNFK-NH2, (NP),  which self-assembles into β-sheet-rich nanofibers. In 
aqueous solution, the capability of the NPs to stabilize the hydrophobic anticancer drug 
ellipticine has been already investigated (247). Functionalization by the conjugation of a 
diethyl glycol (DEG) to one end of the C-terminal or both terminals (C- and N-terminals) of 
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the peptide AAP8—herein called as NP-I and NP-II, respectively has been reported (250), as 
shown in Figure 4-1. 
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Figure 4-1 Schematic of the chemical structure of NP (Ac-FEFQFNFK-NH2) and DEGylated forms NP-I 
(Ac-FEFQFNFK—DEG-NH2) and NP-II (Ac-DEG-FEFQFNFK-DEG-NH2). 
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 Additionally, it has been shown that the DEG conjugate of AAP8 is associated with 
increased solubility, stability, and secondary structure β-sheet content of the peptide as well as 
reducing cellular toxicity (182). In our previous study, AAP8, was shown to be a possible 
carrier for anti-cancer drug delivery. Yet, the peptide had a propensity to initiate toxicity at 
higher concentration (0.1mg/ml). However, the biocompatibility properties of the AAP8 
(NPs) in comparison with modified versions, NP-I and NP-II, have not yet been explored, 
which is a necessary first step in systematic drug delivery application.  
Pirarubicin (tetrahydropyranyladriamycin), originally synthesized in Japan, is an 
anthracycline antibiotic (a derivative of adriamycin), developed to substitute for doxorubicin 
which was first introduced in 1979 (251-253). It is not only more effective against various 
tumors, but also less cardiotoxic (254-256). In addition to its anticancer benefits, pirarubicin's 
hydrophobicity and fluorescence characteristics make it a good candidate to be used to test in 
this study. 
In light of the above information and literature , this study  investigats the interaction of 
AAP8 (NP), its modified versions (NP-I and NP-II) and complexes of all three with 
pirarubicin with the complement system in vitro. The systematic investigation of the 
biocompatibility properties of AAP8 peptide nanoparticles: NP, NP-I and NP-II is reported 
The potential ability of these peptides to be utilized as carriers for the delivery of the 
hydrophobic anticancer drug pirarubicin is also showed. 
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4.2 Materials and Methods 
4.2.1 Peptide-drug complex preparation 
  
The peptide AAP8 (Ac-FEFQFNFK-NH2) and the two diethylene glycol (DEG) (–NH–CH2–CH2–
O–CH2–CH2–O–CH2–CO–) conjugated versions, NP-I: Ac–FEFQFNFK–DEG–NH2 and NP-II: Ac–
DEG–FEFQFNFK–DEG–NH2, were purchased from CanPeptide Inc. (Montreal, Canada). They were 
characterized for their self-assembling properties in aqueous solution at 0.5 mg/ml. A molecular 
weight of 1147.31 g/mol for AAP8, 1293 g/mol for Ac–AAP8–DEG–NH2, and 1437 g/mol for Ac–
DEG–AAP8–DEG–NH2 were confirmed by mass spectroscopy. The purity of the peptides were 
verified as >98% by liquid chromatography–mass spectrometry. Fresh aqueous peptide solutions were 
prepared by dissolving peptide powder in pure water (18.2 MV, Milli-Q A10 synthesis) at specified 
concentrations, followed by sonication for 10 min. The anticancer agent pirarubicin (99.8% pure) was 
purchased from Sigma–Aldrich (Oakville, Canada) and used as received. Cell culture media, low 
glucose Dulbecco’s modified Eagle’s medium (DMEM), and phosphate-buffered saline (PBS) were 
purchased from HyClone (Ontario, Canada). Fetal bovine serum (FBS) and trypsin–EDTA were 
purchased from Invitrogen Canada Inc. (Burlington, Canada). 
4.2.2 Peptide-pirarubicin complex preparation  
To make the peptide-pirarubicin complexes, a pirarubicin stock solution was first prepared in 
pure tetrahydrofuran (THF). Aliquots of pirarubicine-THF were then transferred into 1.5 ml 
centrifuge tubes, and dried in a gentle stream of filtered air (0.22 mm pore size filter) to form 
a thin film at the bottom of tubes. The fresh peptide solutions were added into the tubes 
containing pirarubicin, to make peptide-pirarubicin complexes consisting of 0.3 mg/ml of 
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each peptide and 0.1 mg/ml pirarubicin, followed by continuous probe sonication at 6W 
power for 10 min. A control of pirarubicin in pure water (without peptide) at the same 
concentration was prepared for comparison. In order to study the toxicity of the complexes at 
a range of concentrations, serial dilution of the complexes in water (2, 4, and 8 times) was 
carried out, while keeping the peptide-pirarubicin ratio at 3:1. 
4.2.3 Cytotoxicity assay 
The Cell Counting Kit-8 (CCK-8; Dojindo, Japan) was used to perform cytotoxicity assays. 
A549 cells (ATCC, USA), a human non-small lung cancer cell line, were seeded onto 96-well 
plates at a density of 8×103 cells per well and treated 24 h later. 20µL of the peptide-drug 
complex was diluted in 80µl of growth media (DMEM containing 10% FBS) and added to 
each well. 48 h after treatment, 10µl of CCK-8 substrate was added to each well and 
incubated for an additional 2 h at 37°C in the dark. Absorbance was measured at a wavelength 
of 450nm with a reference wavelength of 620nm using a microplate reader (FLUOstar 
OPTIMA, BMG, NC). 
4.2.4 Fluorescence, flow cytometry, and confocal microscopy 
The fluorescence of pirarubicine was detected by FL2 channel (585/42 nm bandpass filter). At 
least 15000 events were recorded for each sample. The cellular uptake of the peptide-drug 
complexes by A549 cells was quantified via flow cytometry (BD Biosciences, BD FACS 
Vantage SE Cell Sorter, USA). Briefly, A549 cells were seeded in 24-well plates at a density 
of 4×104 cells per well, and allowed to attach for 24 h. Then the cells were washed with 
Phosphate Buffered Saline (PBS) and treated with peptide-drug complexes at a drug 
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concentration of 20µg/ml. After 20 min incubation, the cells were washed three times with 
PBS, detached from the culture wells by incubation with 0.25% trypsin-EDTA solution, and 
then fixed with 4% paraformaldehyde (PFA) in PBS prior to flow cytometry analysis.  
Subcellular localization of peptide-drug complexes was analyzed by confocal microscopy 
(Zeiss LSM 510, Canada) using a 63X objective and a slice thickness of 300nm. A549 cells 
were seeded in 35mm glass bottom dishes (MatTek, MA, USA) at a density of 1×105 cells per 
ml, and allowed to attach for 24 h. The cells were treated with drug complexes and controls 
for 20 min and washed three times with warm PBS and fixed with 4% PFA for 20 min, 
followed by washing with PBS and adding DAPI (Sigma-Aldrich, Oakville, Canada) to stain 
the cell nuclei. Pirarubicin was excited at 488 nm and detected through the 570–630 nm band 
path ﬁlter. DAPI was excited at 405 nm and were visualized by 420–480 nm band path ﬁlter. 
4.2.5 Haemolysis studies 
Haemolysis experiments were carried out by using approximately 5mL of fresh human 
anticoagulant treated blood. The blood is centrifuge at 1500 rpm for 10 minutes and washed 
three times by adding Dulbecco’s Phosphate Buffered Saline (DPBS). After washing, red 
blood cells (RBCs) are isolated and suspended in DPBS to the original volume and then 
diluted further with DPBS to make a 5% hematocrit solution. Varying concentrations of the 
peptide (800 µl) were added to the RBCs (200 µl). DPBS and water served as positive and 
negative controls, respectively. After incubation for 2 hours all the samples were then 
centrifuged and the supernatant was removed and placed into a clean cuvette and the 
absorbance was measured at 541 nm. The haemolysis given by the water solution was 
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considered to be 100% while the hemolysis given for the DPBS solution was taken as 0%.  
 
4.2.6 Complement system activation studies 
In order to determine the amount of complement activation caused by the peptides and the 
peptide-drug complexes in vitro, four complement protease products (C4d, SC5-b9, Bb and 
MBL) were analyzed using enzyme-linked immunosorbent assay kits from Quidel Corp, (San 
Diego, CA, USA) and ALPCO Diagnostics kit (Salem, MA, USA). Peptide samples were 
incubated with human serum at a volume ratio of 1:5 with a final volume of 1ml in a shaking 
incubator (100 rpm) for 60 minutes at 37°C. The samples were then diluted further with 
Sample Diluents according to the manufacturer’s instructions to determine the amount of C4d, 
Factor B, SC5b-9 or active mannan-binding protein that was formed by the complement 
system during the incubation. Zymosan (a known complement activator) was used as a 
positive control and human serum by itself was used as a negative control and both were 
assayed in the same way as all the other samples. Standard curves were made for 
quantification of complement activation products by using the assigned concentration of each 
individual standard supplied by the manufacturer and validated. The slope, intercept and 
correlation coefficient of the derived best fit line for SC5b-9, Bb, C4d and MBL standard 
curves were within the manufacturer’s specified range. The efficacy of the treatments was 
determined by comparison with baseline levels using paired t-test. 
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4.2.7 Anaphylotoxin studies 
In order to assess the amount of C3a, samples were incubated with human serum at a 1:5 ratio 
in a shaking incubator (100 rpm) for 60 minutes at 37°C. The samples were then tested 
according to the enzyme-linked immunosorbent assay kits from Quidel Corp. (San Diego, 
CA, USA). The results were then read at 450nm (FLUOstar OPTIMA, BMG, NC). Since C3a 
is resulting factor of the activation of the classical, alternative or lectin complement pathways, 
Zymosan was used as the positive control and human serum was used as the negative control. 
4.3 Results and Discussion 
4.3.1 Cellular uptake and cytotoxicity of peptide-drug complexes 
Different concentrations of pirarubicin at a fixed peptide-to-pirarubicin weight ratio of 3:1 were used 
to form peptide-pirarubicin complexes, and their cellular toxicity was investigated on the lung cancer 
cell line, A549. As shown in Figure 4-2, all the NP-pirarubicin complexes (i.e. NP-, NP-I- and NP-II-
pirarubicin complexes and pirarubicin-water in the absence of peptide (control)) showed very acute 
cytotoxicity at the high pirarubicin concentration of 20 µg/ml. However at concentrations as low as 2.5 
µg/ml, the viability of cells treated by NP-I- and NP-II-pirarubicin complexes is significantly lower 
than those treated by unmodified NP-pirarubicin or pirarubicin in water.  
This might be due to two main reasons: first, the toxicity of unmodified NP is higher in 
comparison to the modified versions; second, the solubility of DEGylated peptides, is higher 
compared with naked peptides. The higher hydrophilicity in DEGylated peptides could 
stabilize the pirarubicin which thus remains suspended in aqueous media longer by slow 
release of pirarubicin from its complex, which in turn delays the drug contact with adhesive 
cells and thus lowers the toxcicity to non-cancer cells. It is worth to mention that the observed 
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results were in accordance to the observation by published paper that partly investigated the 
effect of DEGylation on toxicity and encapsulation of a hydrophobic drug, ellipticine 
 
 
 
Figure 4-2 Cytotoxicity of NP, NP-I and NP-II and their complexes with the drug pirarubicin were 
measured against the lung cancer cell line A549. Error bars represent standard error of mean (SEM) of 
three independent experiments. * denotes statistically significant difference compared to the negative 
control, non-treated cells, as determined by two-sample t-test (p<0.05). Pira = pirarubicin. 
Fluorescence microscopy images, Figure 4-3 A-E and flow cytometry results Figure 4-3 F 
also support the results of the cytotoxicity assay. As shown in Figure 4-3 F, the cellular 
uptake of pirarubicin at a concentration of 20µl/ml complexed with each of the three peptides 
is similar, as measured via flow cytometry. However, almost an 8-fold increase in pirarubicin 
uptake was observed when the drug is complexed with peptides compared with the drug in 
water. A similar conclusion can be drawn from the microscopy images. In all three cases, the 
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peptides mediated the nuclear uptake of pirarubicin, represented as violet areas (merged), as 
the result of localization of pirarubicin (red) in stained nuclei (blue). In the case of pirarubicin 
in water, Figure 4-3 B, the cells’ nuclei were only partially covered by pirarubicin. Confocal 
fluorescent microscopy additionally confirmed the nuclear uptake of pirarubicin (red) when 
complexed with the peptides as shown by its co-localization with the nucleus (blue), creating 
a pink colour,  Figure 4-3 G-I. Furthermore, the images demonstrated equal uptake of 
pirarubicin-peptide complex, irrespective of the peptide modification. It is worth mentioning 
that the range of concentrations used in all of conducted experiments is highly exceeding the 
dose used for therapeutic purposes (i.e. < 2.5μg/ml). 
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Figure 4-3 Fluorescence microscopy images (A-E) and flow cytometry results (F). Cellular uptake of 
pirarubicin are shown in the fluorescence microscopy images of nontreated cells (A), cells treated with 
pirarubicin in water (B), NP-pirarubicin complex (C), NP-I-pirarubicin complex (D), NP-II-pirarubicin 
complex (E). Violet areas are the result of localization of pirarubicin (red) in stained nuclei (blue). (F) 
Mean fluorescence intensity of uptaken pirarubicin in cells treated with different complexes and controls 
measured by FACS.  Error bars represent standard error of mean (SEM) of three independent 
experiments. N.T. = non-treated cells, Pira-W= pirarubicin in water. (G-I): Confocal microscopy of A549 
cells treated with NP-pirarubicin complexes. Violet nucleus (I) implies the co-localization of pirarubicin 
(red) (H) and DAPI (blue) (G) at the same confocal layer. Similar images were obtained for NP-I-
pirarubicin and NP-II-pirarubicin complexes, confirming the presence of pirarubicin inside the nucleus. 
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4.4 Biocompatibility Evaluation of Self-assembling Peptides 
4.4.1  Haemolysis 
Haemolysis is a crucial factor in evaluating the biocompatibility of NPs. When determining 
the toxicity, a ratio of 5% or less haemolytic activity is considered biocompatible (257). In the 
present study, the haemolytic potential of the NP and its DEGylated versions with and without 
drug were investigated. As shown in Figure 4-4 A, NP-I did not show any haemolytic activity 
even at the highest measured concentration of 60μg/ml, whereas NP and NP-II showed some 
haemolytic activity (6.33 and 7.56%, respectively) at the same concentration. As discussed in 
Sadatmousavi et al. the critical aggregation concentration increases with increasing DEG 
conjugation which increases hydrophilicity. Therefore, DEGylation facilitates more organized 
self assembly and could prevent aggregation (43). Our results partially agree with this; 
however, in a biological environment, we did not observe that DEG conjugation to both ends 
of AAP8 (NP) provides more stable structure in terms of haemolytic activity.  This could be 
due to the higher surface concentration of DEG in assembled NP-II polymers. Therefore, 
these results show that a narrow range of DEG concentration can improve the NP's 
haemocompatibility, and a higher concentration of DEGylation can have a drawback. This 
confirms the importance of careful modification of the NP and the erythrocyte's sensitivity to 
small changes in the NP's structure.  
For drug delivery applications, the effect of the drug as well as the drug-peptide complexes 
should be evaluated. Figure 4B demonstrates the peptides' ability to form a non-haemolytic 
complex with pirarubicin. Pirarubicin itself is haemolytic at concentrations of 10 µg/mL and 
higher (data not shown here). Again NP-I complexed with pirarubicin shows less haemolytic 
activity compared to two other peptides, highlighting the importance of precise modification.  
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Figure 4-4 (A) Haemolytic activity of NP and its modified versions (NP-I and NP-II) alone or (B) in 
complex with the anticancer drug pirarubicin. Error bars represent standard error of mean (SEM) of 
three independent experiments. * denotes statistically significant difference compared to the non modified 
peptide NP, as determined by two-sample t-test (p<0.05). 
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4.4.2 Complement system activation  
The complement system is one of the key effector mechanisms of humoral and innate 
immunity. It consists of several, generally inactive, serum and cell surface proteins which are 
activated only in the presence of pathogens to generate products that mediate a variety of 
effector functions. Therefore, not surprisingly, the majority of the consequences of 
complement activation result from the pharmacological effect of some of the activated 
components. Accordingly, clarification of the potential to activate complement can be used as 
one decisive factor in testing the biocompatibility of a variety of nanoparticles. Different 
types of nanoparticles especially polymers, have been used in medicine for targeted or 
controlled release of various drugs and diagnostic agents and thus have been assessed for 
complement activation (258-261). Here, the effect of NP and its modifications—with and 
without drug pirarubicin—on the three major complement pathways is reported . 
 
After incubation with human serum, Bb and C4d concentrations were measured to assess 
the complement system activation of peptides via alternative and classical pathways, 
respectively. As shown in Figure 4-5 A-B, no complement activation was observed for the 
classical, and alternative pathway of  each peptide (NP, NP-I , NP-II) and their complexes 
with drug. The anti-cancer drug pirarubicin had the classical activity because of its 
hydrophobic nature. This could be due to binding of C1q (main recognition unit of classical 
pathway) to the peptides surface via electrostatic or hydrophobic interactions (264). 
Therefore, these results at least partially agree with the published literature on complement 
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system activation which indicates hydrophobicity can trigger activation of the classical 
pathway.  The MBL pathway was assessed by measuring the amount of functional MBL 
oligomer remaining in the solution. When the pathway is activated, MBL will bind to the 
surface of the invading particle making it incapable of further binding. After incubating the 
samples with human serum for an hour to allow time for MBL to bind to the surface of the 
peptides and peptide complexes, the amount of remaining functional MBL oligomer was 
measured. Figure 4-5 C shows that there is between 600 and 800 ng/mL of functional MBL 
oligomer remaining in the positive control and for the negative control all the functional MBL 
oligomer remains. For our samples, however, there was some lectin activation for NP per se 
with no lectin activation when complexed with drug.  Complement activation via the lectin 
pathway was not observed for NP-I and NP-II peptides and their respective complexes, Figure 
4-5 C. This could be due to the charged side of the peptide binding to the MBL (265). When 
the NP peptides were complexed with pirarubicin, no activation was seen for the NP, NP-I 
and NP-II complexes.  
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Figure 4-5 Complement activation of classical (A), alternative (B), and mannan binding lectin (C) 
pathways of the NPs (60 µg/ml) or in complex with pirarubicin. Error bars represent standard error 
of mean (SEM) of three independent experiments. * denotes statistically significant difference 
compared to the negative control , as determined by two-sample t-test (p<0.05). 
 
These findings show that, overall, the NP-I complex is the most promising drug delivery 
vehicle in terms of three  pathways. In addition, these results illustrate that NPs with a 
different combination of DEG groups produced different levels of complement activation, 
probably resulting from the different physico-chemical characteristics of the modified NPs. It 
is worth  noting that the anti-cancer drug pirarubicin alone in water did not trigger the 
terminal, alternative, lectin and terminal attack pathways. Nevertheless, it activated the 
classical pathways, which is in agreement with the rest of the data. 
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4.4.3 Anaphylotoxin activation 
After activation of any of the complement pathways, the C3 protein is eventually split into 
two fragments, C3b and a potent anaphylotoxin C3a. Therefore, the presence of C3a in a test 
sample proves that NPs can activate complement by any pathway. C3b can participate in the 
formation of a new enzyme, C5 convertase, which cleaves C5 to C5b, which drives the rest of 
the common terminal pathway, and C5a, another very potent anaphylotoxin. One outcome of 
C5b production is cell killing by forming a MAC. However, a large amount of the C5b 
generated with in vitro samples is diverted to the fluid phase by reacting to S protein to form 
soluble SC5b-9 which can be measured as proof of terminal pathway activation. An important 
point is that for each mole of detected SC5b-9, an equal number of moles of C5a are 
generated. C5a is a small, sticky and exclusive molecule with a short half-life and thus is 
difficult to measure directly. In contrast, SC5b-9, as a marker for C5 cleavage, is an extremely 
stable soluble macromolecular complex and can be used as a marker for C5a anaphylotoxin 
generation. Accordingly, to further assess the in vitro extent of NP-induced activation of 
complement, SC5b-9 and C3a were evaluated. 
SC5b-9 concentration was measured after incubation with human serum. As shown in 
Figure 4-6 A, it was found that NP-II and its complex effectively activate the complement 
terminal attack complex. However, NP and NP-I formulations as well as their complexes with 
pirarubicin did not activate the terminal pathway of complement system with respect to the 
negative control and were significantly less than Zymosan (positive control). High activation 
of the terminal attack pathway by NP-II in comparison with NP-I highlights the importance of 
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surface density of DEG for modification of nanoparticles in order to reduce bio-
incompatibility. Similar results were observed, as expected, for C3a anaphylotoxin 
production, Figure 4-6B.  
 
 
Figure 4-6 Complement (A) Complement activation of the terminal pathway by the NPs alone (60 µg/ml) 
or in complex with pirarubicin. Bars represent the mean concentration of SC5b-9, a biomarker of C5a 
through both the classical and alternative pathways. (B) Anaphylatoxin C3a assay comparing the 
concentration of C3a in NP, NP-I and NP-II treated samples, as well as positive (Zymosan) and negative 
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control (Human serum). Error bars represent standard error of mean (SEM) of three independent 
experiments. * denotes statistical significance compared to the negative control, as determined by two-
sample t-test (p<0.05). 
 
In summary, NP and NP-I performed similarly in all pathways of complement activation 
but the lectin pathway. NP per se produced the small activation of the lectin pathway with no 
lectin activation when complexed with drug. However, NP-I and its complex did not activate 
the classical, alternative, lectin and terminal pathways of complement system, most probably 
because of proper functionalization by DEG conjugation with more organized self assembly, 
and less hydrophobicity, resulting in stable fibers in the complex with drug in aqueous 
solution. Thus these results indicate NP-I is a potential candidate for a hydrophobic anticancer 
drug delivery system. This highlights the importance of proper modification in drug delivery 
systems.  
4.5 Conclusions 
The in vitro biocompatibility of NPs and their modified versions were systematically 
investigated. Their potential to be used as carriers for the anticancer drug pirarubicin was also 
shown. The nuclear uptake efficiency of pirarubicin was enhanced upon co-assembling with 
NP and its DEGylated versions (NP-I and NP-II). The DEGylated NP-pirarubicin complexes 
showed acute toxicity at pirarubicin concentrations as low as 2.5 µg/ml, however the toxicity 
of NP-pirarubicin at this concentration was  33%. It was also found that the one terminal 
DEGylated peptide, NP-I, , showed the best compatibility in terms of haemolytic activity, and 
complement activation. Furthermore, the DEGylation did not compromise the efficacy of the 
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nuclear uptake of its load (pirarubicin). These results highlight the importance of modification 
to NPs in drug delivery. Based on these data, I suggest the use of NP-I as an anticancer drug 
delivery vehicle for future applications. Based on these data, it is suggested that the use of 
NP-I as an anticancer drug delivery vehicle for future applications. It is proposed that the in 
vitro data presented here will help in predicting the effects of these NPs in vivo.  
 
 
 
 
 
 
 
 
 
 
 81 
 
Chapter 5* 
Nanotoxicity of Self-Assembling EAK16-II and EK8 
Peptides and Anticancer Drug Pirarubicin 
5.1 Introduction 
A major goal of modern nanotoxicology in pharmaceutical applications is to enhance 
therapeutic safety by understanding the relationship between biophysicochemical properties 
of nanomaterials and the outcomes resulting from the contact of these nanosized materials 
with biological systems. In the past few years, cell culture systems have been the main focus 
of nanotoxicology studies. These data are necessary but not sufficient for assessing toxic 
responses. As a result, nanotoxicology studies as a sub-discipline of nanotechnology has 
recently undergone a dramatic expansion as the importance of biocompatibility has become 
obvious for the correct functioning of nano sized materials.  
 Currently, various drug delivery carriers have been developed for cancer chemotherapy 
such as liposomes, polymeric micelles, albumin-bound nanoparticles and lipoproteins, all 
requiring acceptable bio-compatibility and low bio-activity (266-270).  Among them, self-
assembling peptides- serendipitously discovered 20 years ago- have been extensively 
explored as one of the potential candidates that can be used as a building block for a variety of 
applications such as materials science (266), bioengineering, tissue engineering (271-274), 
cell culture and of particular interest to this thesis drug delivery (239-248, 275).  
                                                     
* This chapter is adapted from a paper draft " Sheva Naahidi, Yujie Wang, Mousa Jafari, Lu Sheng, Yongfang Yuan, P. Chen, 
Nanotoxicity of Self-Assembling EAK16-II and EK8 Peptides and Anticancer Drug Pirarubicin"  
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These peptides are capable of self-assembling spontaneously into various microstructures in 
aqueous solution and have triggered numerous studies aimed at synthesizing novel self-
assembling peptides and characterizing the resulting microstructures (276). Other advantages 
of these peptide-based carriers are possible biocompatibility and low toxicity, as well as ease 
of preparation (277). Therefore, self-assembling peptides have obvious advantages which can 
play an important role in nanoparticle delivery systems. One of these promising classes of 
peptides is self-assembling ionic-complementary peptides (278). These ionic- complementary, 
self-assembling, peptides are characterized by either alternating arrangement of charged 
residues or hydrophobic/hydrophilic amino acid residues (279). These unique repetitive amino 
acid sequences, both ionic and hydrophobic, allow them to self-assemble into stable 
nanostructures, which may provide a protected and stable environment for the drug molecules 
(271-273).  
Two such promising peptides are EAK16-II and EK8 which both contain all 
complementary amino acid pairing in the sequence and thus the name amino acid pairing 
(AAP) peptides. The molecular structure of both peptides are shown in Figure 5-1. 
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Figure 5-1 Chemical structure of ionic-complementary peptide EAK16-II (n-AEAEAKAKAEAEAKAK-
c) (A) and EK8 peptide (n-EEKKEEKK-c) (B) 
 
Pirarubicin is used as a candidate to test our drug delivery system using EAK and EK as 
carriers. 
However, prior to their utilization as vehicles for drug delivery, the nanotoxicity of these 
peptides needs to be addressed by understanding their effects on biological systems. In vivo 
systems are expensive and the nanomaterial-biological entity interaction, such as peptides and 
cells, could trigger unique results such as biodistribution, clearance, and immune responses. 
Therefore, initial in vitro studies can precede the need for the wider range of in vivo studies. 
Additionally, in vitro examinations are necessary first step to rationalize whether there are 
effects which would be observed in vivo and they can be used to translate these data into a 
predicted response model in patients. As a result, these experiments are critical and essential 
towards our efforts to develop a novel, effective nano medicinal drug delivery system. 
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 So far, there have not been any comprehensive studies on the possible nanotoxicology of 
EAK and EK; therefore, further study was required to understand how  
to use these two peptides in systematic drug delivery. Complement is an important effector 
arm of both innate and acquired immunity (280). Anaphylatoxins and chemoattractants, C3a 
and C5a, are generated as a outcome of complement activation and can provoke anaphylaxis 
in systematically infected individuals (281). In addition to anaphylatoxin release, the terminal 
part of the complement pathway generates C5b-9 complexes (280) and these have the 
capability to trigger non-lytic stimulatory responses from endothelial cells (237), and 
modulate endothelial regulation of hemostasis and inflammatory cell recruitment. 
In light of the above information and published articles, the in vitro biocompatibility and 
toxicity of both self-assembling ionic-complementary peptides EAK16-II and EK8  along 
with the anticancer agent Pirarubicin were evaluated. Based on reasonable and tolerable in 
vitro data between both peptides candidates, EK8 was further selected to be evaluated 
systematically in vivo for its immunocompatibility and bioavailability.  The potential ability 
of these peptides to be utilized as carriers for the delivery of the hydrophobic anticancer drug 
pirarubicin is also shown. Nuclear uptake of peptide-pirarubicin complexes by A549 cells was 
shown and confirmed by both fluorescence and confocal microscopy respectively. Finally, 
EK8 peptides had favorable biocompatibility and poor bio-activity in vivo.  
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5.2 Materials and Methods 
5.2.1 Sample preparation  
The peptides EAK and EK (purity>98%) were purchased from CanPeptide Inc. (Montreal, 
Canada) and used without further purification. Both peptides were protected by acetyl and 
amino groups at their N-terminus and C-terminus, respectively. The anticancer agent 
pirarubicin (99.8% pure) was purchased from Sigma–Aldrich, (Oakville, Canada) and was 
used unaltered. The powdered peptides were dissolved in pure water (18 MΩ; Millipore Milli-
Q system) to obtain a fresh peptide solution at a concentration of 0.5 mg/ml (source). The 
solution was then sonicated in a bath sonicator (Branson, model 2510) for 10 min. To make 
the peptide-pirarubicin complexes, a pirarubicin stock solution was first prepared in 
tetrahydrofuran (THF) and then transferred into a glass vial, and dried in a gentle stream of 
filtered air (0.22 mm pore size filter) to form a thin film at the bottom of the vial. The freshly 
prepared peptide solution was added into the vial containing pirarubicin, to make peptide-
pirarubicin complexes consisting of 0.5 mg/ml EAK or EK8 and 0.1 mg/ml pirarubicin, 
followed by mechanical stirring at 900 rpm for 24 h. These complexes were then serially 
diluted in water 2, 4, and 8X (while keeping the peptide-pirarubicin ratio at 5:1) to prepare a 
range of concentrations for toxicity studies. 
5.2.2 Cytotoxicity Assay 
Non-small cell lung carcinoma cells (A549) were obtained from American Type Culture 
Collection (ATCC, Manassas, VA, USA). To perform cytotoxicity assays, a Cell Counting 
Kit-8 (CCK-8 from Dojindo, Japan) was purchased. The human lung carcinoma cell line 
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A549 was seeded at a density of 8×103 cells per well onto 96-well plates. To each well, 20µL 
of the peptide-drug complex diluted in 80µl of growth media (Dulbecco’s Modified Eagle 
Medium containing 10% fetal bovine serum) was added, 24 h after cell seeding. After 48 h of 
treatment, CCK-8 substrate (10µl) was added to each well and incubated for an additional 2 h 
at 37°C in the dark. Using a microplate reader (FLUOstar OPTIMA, BMG, NC), absorbance 
measurements were taken at a wavelength of 450nm with a reference wavelength of 620nm. 
5.2.3 Hemolysis studies 
Approximately 5mL of anticoagulant treated, fresh human blood was used for hemolysis 
studies. Prior to use, the blood was centrifuged at 1500rpm for 10 minutes and washed three 
times with Dulbecco’s PBS (DPBS). Red blood cells (RBCs) were then isolated and 
suspended in DPBS to the original volume and then diluted further with DPBS to make a 5% 
hematocrit solution. Varying concentrations of the peptide in 800µl of DPBS, water (positive 
control) or DPBS (negative control) were added to the 200µl of RBCs and incubated for two 
hours. All the samples were then centrifuged and the supernatant was removed and placed 
into a clean cuvette; subsequently, the absorbance was measured at 541nm. Hemolysis in the 
water solution was considered 100% while the hemolysis given by the DPBS solution was 
considered 0%. The results were expressed as percentage hemolysis. 
5.2.4 Complement system activation studies 
The amount of complement activation caused by each peptide and the (EAK or EK) peptide-
drug complexes in vitro were determined by measuring the active forms of four complement 
products (C4d, SC5-b9, Bb and MBL) using enzyme-linked immunosorbent assay kits from 
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Quidel Corp, (San Diego, CA, USA) and ALPCO Diagnostics kit (Salem, MA, USA). Peptide 
samples were added to human serum at a volume ratio of 1:5 and incubated in a shaking 
incubator (100 rpm) for 60 minutes at 37°C. Three time points were measured (1-3 hours). 
However, there was no increase at later time points.  Human serum alone and zymosan (a 
known complement activator) were used as negative and positive controls, respectively. The 
results were then read at 450nm (FLUOstar OPTIMA, BMG, NC). Standard curves were 
made for quantification of complement activation products by using the assigned 
concentration of each individual standard supplied by the manufacturer and validated. 
Quantification of complement activation products were made by making standard curves 
using the assigned concentration of each individual standard supplied by the manufacturer and 
validated. The slope, intercept and correlation coefficient of the derived best fit line were 
within the manufacturer’s specified range for SC5b-9, Bb, C4d and MBL standard curves. 
The efficacy of the treatments was determined by comparison with baseline levels using 
paired t-test. 
5.2.5 Anaphylatoxin studies 
The samples were incubated with human serum in a 1:5 ratio in a shaking incubator (100 rpm) 
for 60 minutes at 37°C to assess C3a formation. Enzyme-linked immunosorbent assay kits 
from Quidel Corp. (San Diego, CA, USA) were then used to measure C3a concentrations. The 
results were read at 450 nm (FLUOstar OPTIMA, BMG, NC). Given that C3a and C5a can 
result from the activation of the classical, alternative or lectin complement pathways, human 
serum and zymosan were used as negative and positive controls, respectively. 
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5.2.6 Confocal and fluorescence microscopy 
Confocal microscopy (Zeiss LSM 510, Canada) was used to analyze the subcellular 
localization of peptide-drug complexes, using a 63X objective and a 300nm slice thickness. 
A549 cells (1×105 cells per ml) were seeded in 35mm glass bottom dishes (MatTek, MA, 
USA), and allowed to attach for 24 h. After treatment with drug complexes and controls (non-
treated cells and pirarubicin) for 20 min and washing three times with warm DPBS, the cells 
were fixed with 4% PFA for 20 min. This was followed by washing with PBS and adding 
DAPI (Sigma-Aldrich, Oakville, Canada) to stain the cells’ nuclei. Pirarubicin and DAPI were 
excited at 488 nm and 405 nm, respectively, and detected through the 570–630 nm and 420-
480 nm band path ﬁlters, respectively. 
For fluorescence microscopy, after 20 min incubation with complexes, the cells were 
washed three times with PBS, and fixed with 4% PFA, followed by adding DAPI (Sigma-
Aldrich, Oakville, Canada) to stain the cells’ nuclei. An inverted fluorescence microscope 
(Zeiss AxioObserver Z1, Canada) was used to evaluate the complex uptake using a 40X 
objective.  
5.3 Results and Discussion 
5.3.1 Cytotoxicity of peptides 
Cytotoxicity results in Figure 5-2 showed that the cells treated by both peptides had almost 
the same viability as that of non treated cells, indicating the safety of peptides even at 
relatively high concentrations i.e., 0.1 mg/ml. Similar results were obtained for the cells 
treated by Pirarubicin in water due to its very limited solubility. However, the EAK-pira and 
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Ek8-pira complexes showed strong toxicity at drug concentrations of 0.02 mg/ml (1xd). 
Diluting the complexes to half (2xd) showed better  performance of EK8, compared to EAK, 
in based on pirarubicin delivery, leading to 55% toxicity in the treated cells (versus 38% for 
EAK-pira).  Further dilution of the complexes (4xd and 8xd) resulted in a reduction in  
viability to 80% .  
 
 
Figure 5-2 Cytotoxicity of EAK16-II and EK8 and their complexes with pirarubicin at different 
concentrations. Cytotoxicity of EAK16-II and EK8 per se and with pirarubicin were measured against the 
lung cancer cell line A549. Three independent experiments were performed for each data point. 1xd 
represents peptide/pirarubicin concentration of 0.1/0.02 mg/ml. 
5.3.2 Haemolysis 
Hemolysis is the rupture of the RBC’s membrane, resulting in the release of hemoglobin and 
other internal components into the surrounding fluid; therefore, it is a crucial factor in 
evaluating the biocompatibility of biomaterials. It is also a common occurrence in serum 
samples and may compromise the laboratory’s test parameters. When determining the 
hemolytic activity, a ratio of 5% or less is considered biocompatible (257). In the present 
study the haemolytic potential of the self-assembling/co-assembling peptides EAK and EK on 
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untreated human blood with was investigated. Water was used to lyse the red blood cells as 
positive control and D-PBS was used as the negative control. The amount of hemoglobin 
released was measured by the absorbance at 541 nm. 
 
 
Figure 5-3 Haemolytic activity of self-assembling peptides EAK16-II and EK8 and their complexes with 
anticancer drug pirarubicin at different concentrations, in peptide:drug weight ratio of 5:1. Error bars 
represent standard error of mean of three independent experiments. Abbreviations: SEM: standard error 
of mean. 
Although the concentration of both EAK and EK peptides dispersion was high, they did not 
show any observational hemolytic activities in the RBC in the experimental range Fig 5-3. 
Their complexes with anticancer drug Pirarubicin at concentrations as high as 0.1mg/ml 
which is above the therapeutic concentration (0.05mg/ml), showed mild hemolytic activity for 
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drug Pirarubicin did not show any haemolytic activity but EAK did show small amount of 
activity. 
5.3.3 Complement system activation 
The complement system, as one of the key effector mechanisms of humoral and innate 
immunity, consists of several, generally inactive, serum and cell surface proteins which are 
activated only under particular conditions. Different types of nanoparticles, especially 
polymers, have been used in medicine for targeted or controlled release of various drugs and 
diagnostic agents, of which many have been assessed for complement activation (258-261).  
 After incubation with human serum, C4d, MBL and Bb concentrations were measured to 
assess complement system activation via classical, lectin and alternative pathways. As shown 
in Fig. 5-4A, complement activation via the classical pathway was not observed for both 
peptides per se as well as EK complex, Fig.5-4B ; but  EAK complex with pirarubicin  did 
activate classical pathway which may be due to binding of C1q (main recognition unit of 
classical pathway) to the peptide via electrostatic or hydrophobic interactions (264).   
The MBL pathway was assessed using a kit that measures the amount of functional MBL 
oligomer remaining in the solution. When the pathway is activated, the oligomer will bind to 
the surface of the invading particle rendering it dysfunctional. After incubating the samples 
with human serum for an hour to allow time for the oligomer to bind to the surface of the 
peptides and peptide complexes, the amount of remaining functional MBL oligomer was 
measured. Figs. 5-4 C-D show that for the positive controls, there are very little functional 
MBL oligomer remaining and for the negative controls all the functional MBL oligomer 
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remained. For our samples, there is activation for both peptides EAK and EK per se (Fig. 5-
4C). While there was lectin pathway activation; nevertheless, they did not reach the 
“threshold” level of activation required for the next step of complement activation because 
there was no Bb activation for both peptides and their complexes (Fig. 5-4E-F). It worth  
mentioning that even with longer incubation times  the results remained the same. Finally, as 
shown in Fig. 5-4D, there was not any lectin activation for both peptidepira complexes. This 
may be due to the fact that pirarubicin can be stabilized by ionic interaction with the 
negatively charged residues (glutamic acid E in these cases) of the peptides. Thus, the self-
assembling peptides EAK and EK could stabilize the hydrophobic drug in aqueous solution as 
was the case reported for EAK16-II and ellipticine (282, 283). 
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Figure 5-4 Complement activation of classical (A-B), mannan binding lectin (C-D) and alternative (E-F),  
pathways of the EAK16-II and EK8 (0.05 mg/ml) after 1 hour. Error bars represent SEM of three 
independent experiments. * denotes statistically significant difference compared to the negative control 
(DPBS), as determined by two-sample t-test (p<0.05). Abbreviations: SEM: standard error of mean. 
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5.3.4 Anaphylotoxin activation 
As an eventual outcome of either classical, lectin or alternative pathway activation, the C3 
protein is split into two fragments, C3b and a potent anaphylotoxin C3a. Therefore, the 
production of C3a in a test sample proves that peptide nanoparticles can activate. On the other 
hand, C3b can participate in the formation of a new enzyme, the C5 convertase, which cleaves 
C5 to C5b which drives the rest of the common terminal pathway, and C5a is also a very 
potent anaphylatoxin. One outcome of C5b production is cell killing by forming a MAC. 
However, a large amount of the C5b generated with in vitro samples is diverted to the fluid 
phase by reacting to S protein to form soluble SC5b-9 which can be measured as proof of 
terminal pathway activation. An important point is that for each mole of detected SC5b-9, an 
equal number of moles of C5a are generated. C5a is a small, sticky and exclusive molecule 
with a short half-life. In contrast, SC5b-9, as a marker for C5 cleavage, is an extremely stable 
soluble macromolecular complex and can be used as a marker for C5a anaphylotoxin 
generation. Accordingly, to further assess the in vitro extent of EAK and EK induced 
activation of complement, SC5b-9, C3a and C5a production were evaluated.  
After incubation with human serum, the SC5b-9 concentration was measured to assess the 
complement system activation of EAK and EK peptides and their complexes with pirarubicin. 
As shown in Fig.5-5A-B, it was found that EAK and EK alone did not activate the terminal 
pathway of complement system similar to human serum (negative control) and were 
significantly less than Zymosan (positive control). Similar results were observed, as expected, 
in regards to C3a and C5a anaphylotoxins. However, EAK peptide complexed with anti-
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cancer agent pirarubicin did activate the terminal pathway, whereas EK complex did not 
activate the terminal pathway Fig.5-5B.  In the light of above information, further 
experiments examined peptides complex, peptides-pira, for their ability to activate 
anaphylotoxin C3a and C5a  
As shown in Fig. 5-5C, initial anaphylotoxin C3a production was not observed for both 
peptides complexes. However, EAK complexed with pirarubicin did induce production of 
anaphylotoxin C5a which confirms the observations seen in the SC5b-9 testing (Fig 5-5D). In 
summary, the ionic, complementary self-assembling peptide EK8 did not activate the 
complement system in vitro alone or complexed with pirarubicin highlighting the potential of 
this peptide to be used as a drug delivery system, while EAK did induce complement 
activation when complexed with drug.  
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Figure 5-5 Complement activation of the terminal pathway by the EAK 16-II and EK8 peptides (A) and 
their complexes with pirarubicin (B)  at a concentration of 0.05 mg/mlafter 1 hour. Bars represent the 
mean concentration of SC5b-9, a biomarker of C5a production . C-D) Anaphylatoxin assay comparing the 
concentration of C3a and C5a induced by both peptides-Pira treated samples, and positive (Zymosan) as 
well a negative control (Human serum) Error bars represent SEM of three independent experiments. * 
denotes statistical significance compared to the negative control, as determined by two-sample t-test 
(p<0.05). Abbreviations: SEM: standard error of mean; D-PBS: Dulbecco`s Phosphate Buffered Saline. 
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5.3.5 Confocal and fluorescence microscopy 
Confocal fluorescent microscopy confirmed the nuclear uptake of anti-cancer drug pirarubicin 
(tetrahydropyranyladriamycin) when complexed with the peptides as shown by its co-
localization with the nucleus (Fig. 5-6 A-C). 
 
 
Figure 5-6 Confocal microscopy of A549 cells treated with EK-pirarubicin complexes confirming the 
presence of pirarubicin inside the nucleus. Violet nucleus (C) implies the co-localization of pirarubicin 
(red) (B) and DAPI (blue) (A) at the same confocal layer. Fluorescence microscopy images (D-F). Cellular 
uptake of pirarubicin are shown in the fluorescence microscopy images of nontreated cells (D), cells 
treated with pirarubicin in water (E), EK-pirarubicin complex (F), Violet areas are the result of 
localization of pirarubicin (red) in stained nuclei (blue).  Abbreviations: Pira-W= pirarubicin in water. 
DAPI: 6-diamidino-2-phenylindole. 
Pirarubicin's hydrophobicity and fluorescence characteristics make it a good candidate to be 
used for a drug delivery system using EAK and EK as its carrier. The peptide mediated the 
nuclear uptake of pirarubicin, represented as violet areas (merged), as the result of localization 
of pirarubicin (red) in stained nuclei (blue). The range of concentrations used in all of 
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conducted experiments highly exceeds the dose considered for therapeutic purposes (i.e. < 
2.5μg/ml). 
5.4 Conclusions 
The EAK16-II and EK8 peptides’ potential carrier for the hydrophobic anticancer drug 
Pirarubicin was systematically investigated for its biocompatibility and toxicity. It was found 
that EK and its complex with Pirarubicin caused no hemolytic, complement and 
anaphylotoxin activation at the concentration to be considered for a drug delivery system. EK 
peptide Further results also indicated its potential to deliver the drug Pirarubicin into the cell. 
However, EAK pirarubicin complex did activate the classical pathway in significant extent 
and C5a anaphylotoxin suggesting that complement activation did proceed to the later, 
inflammatory, stages which are confirmed by the terminal pathway. The differences in in vitro 
observations can be due to the presence of additional hydrophobic amino acid alanin or the 
effect of length, from 16 amino acid, EAK16-II to 8 amino acids EK. 
Studies are in progress to determine the uptake pathway of the drug and increase the efficacy 
of this novel therapeutic system through more efficient targeting. 
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Chapter 6 
Original Contributions and Recommendations 
6.1 Original Contributions to Research 
This thesis presented the biocompatibility potential of the special classes of self/co-
assembling amino acid pairing peptides as carriers for hydrophobic anti-cancer drug delivery. 
The hematocompatibility and immunocompatibility of the designed peptides as well as their 
toxicity against the human adenocarcinoma lung cancer cell line, A549, were systematically 
investigated  
This thesis investigated the following peptides: (i) AC8 (ii) Two modified (DEGylated) 
versions of AC8 (iii) EAK16-II and EK8. The major contributions and outcomes of each 
peptide are highlighted and summarized in the following parts. 
Biocompatibility of the  AC8 peptide  as a drug carrier 
Although peptide-based nanoparticles have emerged as promising drug delivery systems for 
targeted cancer therapy, the biocompatibility of many of these nanoparticles has not been 
elucidated. Therefore, in this thesis, the in vitro biocompatibility and toxicity of the self/co-
assembling peptide AC8 were evaluated. AC8 showed minimal hemolytic activity (5%) and 
did not cause aggregation of red blood cells. The in vitro assay revealed that AC8 did not 
activate the complement system via the classical or alternative pathway but did activate the 
lectin pathway to a small extent. However, AC8 showed no C3a and C5a anaphylotoxin 
activation suggesting that complement activation did not proceed to the later, inflammatory, 
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stages. The in vivo immunocompatibility and bioactivity of the self/co-assembling peptide 
AC8 in its nanoparticle form has been also evaluated.  
Immuno- and hematocompatibility of AC8-based peptides and potential use for 
anticancer drug delivery  
Recently, amino acid pairing, peptide-based nanoparticles have been introduced as 
promising carriers for hydrophobic anticancer drugs in cancer therapy. The AC8 peptide, with 
eight amino acid in sequence, n-FEFQFNFK-c, is based on the amino acid pairing (AAP) 
design containing 8 amino acids and hence the designated name AAP8. In previous work in 
Pu Chen's  lab, AAP8 nanoparticles (NPs) were modified by conjugation to diethylene glycol 
(DEG), a short segment of polyethylene glycol, in an amino-end-terminal or both-end-
terminal fashion (DEGylated NPs). Yet, the biocompatibility of these amino acid pairing, 
peptide-based NPs in comparison to modified versions has not been extensively studied. Here, 
the in vitro biocompatibilities of the NPs and their modified versions were compared and the 
potential of these peptides as carriers for the hydrophobic anticancer drug pirarubicin was 
demonstrated. The biocompatibilities of the peptide-drug co-assembly complexes were also 
assessed. The toxicity of the NPs, DEGylated NPs, as well as their mixture with pirarubicin 
was tested against the human adenocarcinoma lung cancer cell line, A549. It was found that 
the amino-end DEGylated NP, (NP-I), had superior biocompatibility  to the non-modified 
NPs or two-ended-terminal DEGylated NPs (NP-II). NP-I showed acceptable hemolytic 
activity while NP and NP-II showed marginal and acceptable hemolytic activity (5%), 
respectively. Nuclear uptake of NP-pirarubicin complexes indicated adequate and comparable 
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uptake for all three types of NPs by A549 cells. All three types of NPs did not activate the 
complement system via the classical and alternative pathways of complement system nor did 
they activate the anaphylotoxine C3a.  However, NP-II and its complex effectively activate 
the complement terminal attack complex. The lectin pathway was not activated by NP-I and 
NP-II, but was to a small extent by the non-modified NPs with no lectin activation when 
complexed with drug. These results indicate NP-I is the most promising peptide for use as a 
drug delivery system, highlighting the importance of proper modification in drug delivery 
systems. 
Nanotoxicity of self-assembling EAK16-II and EK8 peptides and anti-cancer drug 
pirarubicin.  
Nanotoxicology testing of nanoparticles is an essential step in their safety assessment for 
biomedical applications. Self/co-assembling peptides, as one of the potential candidates for 
applications in the pharmaceutical industry, have gained considerable attention due to their 
structural diversity, promising diagnostic and therapeutic possibilities in cancer. In this 
regard, in vitro nanotoxicity of the self/co-assembling peptides EAK16-II (EAK) and EK8 
(EK) as well as the in vivo immunocompatibility and bioactivity of the peptide EK8 in its 
nanoparticle form were evaluated to show their potential  us as a carrier for the hydrophobic 
anticancer drug pirarubicin. Both EAK and EK self/co-assembling peptides showed no 
hemolytic activity at therapeutic concentrations and EK did not cause aggregation of red 
blood cells. The in vitro assay revealed that both peptides complexed with pirarubicin did not 
activate the complement system via the lectin or alternative pathway.  EAK pirarubicin 
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complex did activate the classical pathway to a  significant extent whereas EK peptide and its 
complex with pirarubicin did not activate the classical pathway. Although both EAK and EK 
peptides showed no C3a activation, EAK did activate C5a anaphylotoxin  suggesting that 
complement activation did proceed to the later, inflammatory, stages which was confirmed by 
an assessment of terminal pathway activation. Based on the observed in vitro results, EK 
peptide was selected for further in vivo studies. The in vivo immune response assay showed 
that administration of EK to BALB/c mice had no effect on the weight of immune organs or 
body weight of mice at doses less than 0.1mg/kg. This peptide also did not have any effect on 
the expression of CD3+ T-cells and natural killer (NK) cells, the ratio of CD4+/CD8+ T-cells 
and the proliferation of B-cells. The efficiency of the each peptide-pirarubicin complex 
(peptide-pira) was also confirmed by showing a decrease in the viability of lung cancer cells 
treated with peptide-Pira. Here Ireport for the first time experimental results regarding two 
self-assembling peptides, EAK and EK, concluding that EK might be an ideal candidate for 
hydrophobic drug delivery applications given its lack of toxicity and the fact that it is not 
recognized as a foreign molecule, inducing no immune reaction. These results will provide a 
basis in the future for the clinical toxicity testing of this peptide in drug delivery. 
6.2 Recommendations 
The introduction of synthetic materials, used for nanoparticle fabrication among other 
applications, has spawned a new scientific concept within biomaterials, called 
biocompatibility, which delves into understanding the reciprocal relationship between 
materials and biological systems. Peptide based nanoparticles interacting with cells and the 
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extracellular environment can trigger a sequence of biological effects. These effects largely 
depend on their dynamic physicochemical characteristics, which in turn determine the 
biocompatibility and efficacy of the intended outcomes. Because of several important 
structural features of Ionic-complementary peptides, effects of changes on molecular design 
as important factors can be evaluated. These effects include amino acid replacement, 
alteration in charge distribution and variation in peptide chain length, from 8 to 32 amino 
acids in sequence. In the light of above information and based on the studies conducted in this 
thesis, recommended future studies include the following:  
• Biocompatibility evaluation of EAR16II (EAR) as a modified form of EAK16II 
(replacement of lysine to arginine) and screening the effect of R (arginine) amino 
acid in comparison with K (lysine) on biocompatibility of this sequence. 
• Replacement of R amino acid to H inEAH-16II, and screening of this replacement 
for its effect on biocompatibility. 
• Biocompatibility evaluation of EAR8 to address the effect of length, comparing 16 
amino acid EAR16-II to 8 amino acids EAR8. 
o New additional measure for biocompatibility such as thrombogenicity, to 
evaluate the intended peptide's propensity to stimulate platelet activation 
and/or aggregation, its effects on plasma coagulation time, and tendency to 
initiate vascular thrombosis.. Evaluation of platelet activation in response to 
nanoparticle introduction by measuring the release of human platelet factor 4 
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in human plasma (PF4). Evaluation of fibrinogen activation, one of the most 
plentiful proteins in human plasma which activates the coagulation cascade 
and plays a major role in the opsonization process of the complement 
system. Coagulation assays which could be conducted to measure 
biocompatibility are: Prothrombin Time (PT), Activated Partial 
Thromboplastin Time (APTT), and Thrombin Time (TT). 
• 3D cell culturing and toxicity evaluation of designed peptides as opposed to  2D cell 
culturing. This can help to predict more accurate in vivo toxicity.  
• After choosing proper peptide design in terms of biocompatibility, the selected 
peptide can be incorporated with targeting motifs. Then in vitro and in vivo 
biocompatibility evaluations can be applied. 
•  Finding a desirable anti-cancer drug which is compatible with our peptide such that 
in combination they trigger no toxicity or  an extremely low level of toxicity with co 
assembly with selected targeting peptides.  
In vitro and in vivo studies have to be performed in the final design to select and form de 
novo smart nano-delivery systems and move these smart systems from bench to clinical 
studies. 
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